Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery by Kenakin, Terry & Miller, Laurence J.
Seven Transmembrane Receptors as
Shapeshifting Proteins: The Impact of
Allosteric Modulation and Functional
Selectivity on New Drug Discovery
TERRY KENAKIN AND LAURENCE J. MILLER
Molecular Discovery Research, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina (T.P.K.); and
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (L.J.M.)
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266
I. Receptors as allosteric proteins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266
II. The structural organization of seven transmembrane receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267
A. Structure and interaction of ligands with seven transmembrane receptors. . . . . . . . . . . . . . . . . 268
1. Interaction of seven transmembrane receptors with natural ligands. . . . . . . . . . . . . . . . . . . . 268
2. Interaction of seven transmembrane receptors with drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . 270
III. Receptor conformation as protein ensembles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 271
IV. Allosteric transitions within receptor ensembles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272
V. The vectorial nature of allostery. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274
A. Classic guest allosterism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
1. Unique properties of allosteric modulators. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275
2. Allosteric agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 278
3. Seven transmembrane receptor allostery and new drug discovery. . . . . . . . . . . . . . . . . . . . . . 279
4. Therapeutic application of allosteric modulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279
B. Lateral allostery (Dimerization, complexation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280
1. Receptor oligomerization and structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280
a. Interactions of seven transmembrane receptors with other membrane proteins . . . . . . . . 281
b. Influence of the lipid microenvironment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
2. Receptor oligomerization and function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
3. Therapeutic application(s) of receptor oligomers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
C. Cytosolic allostery: functional selectivity and biased ligands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
1. Functional selectivity and structure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
a. Interactions with G proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 283
b. Interactions of seven transmembrane receptors with other cytosolic proteins . . . . . . . . . . 284
2. Operational mechanisms of functional selectivity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
a. Historical perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
b. Ligand-specific seven transmembrane receptor conformations . . . . . . . . . . . . . . . . . . . . . . . 285
c. Biased agonism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286
d. Biased antagonism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
e. Functional selectivity and new drug discovery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289
f. Functional selectivity and drug nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292
3. Therapeutic application of functional selectivity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292
VI. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295
Acknowledgments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 295
Address correspondence to: Terry P. Kenakin, GlaxoSmithKline, 5 Moore Drive, Mailtstop V-287, Research Triangle Park, NC 27709.
E-mail: terry.p.kenakin@gsk.com
This article is available online at http://pharmrev.aspetjournals.org.
doi:10.1124/pr.108.000992.
0031-6997/10/6202-265–304$20.00
PHARMACOLOGICAL REVIEWS Vol. 62, No. 2
Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics 992/3586555
Pharmacol Rev 62:265–304, 2010 Printed in U.S.A.
265
by guest on June 7, 2018
D
ow
nloaded from
 
Abstract——It is useful to consider seven transmem-
brane receptors (7TMRs) as disordered proteins able
to allosterically respond to a number of binding part-
ners. Considering 7TMRs as allosteric systems, affin-
ity and efficacy can be thought of in terms of energy
flow between a modulator, conduit (the receptor pro-
tein), and a number of guests. These guests can be
other molecules, receptors, membrane-bound pro-
teins, or signaling proteins in the cytosol. These vec-
torial flows of energy can yield standard canonical
guest allostery (allosteric modification of drug effect),
effects along the plane of the cell membrane (receptor
oligomerization), or effects directed into the cytosol
(differential signaling as functional selectivity). This
review discusses these apparently diverse pharmaco-
logical effects in terms of molecular dynamics and
protein ensemble theory, which tends to unify 7TMR
behavior toward cells. Special consideration will be
given to functional selectivity (biased agonism and
biased antagonism) in terms of mechanism of action
and potential therapeutic application. The explo-
sion of technology that has enabled observation of
diverse 7TMR behavior has also shown how drugs
can have multiple (pluridimensional) efficacies and
how this can cause paradoxical drug classification
and nomenclatures.
I. Receptors as Allosteric Proteins
Seven transmembrane receptors (7TMRs1) are mole-
cules, situated as intrinsic plasma membrane proteins,
that bind to natural ligands approaching from one mi-
lieu (extracellular) and respond by activating signaling
cascades emanating from molecular interactions in a
distinct (cytosolic) milieu. Their fundamental nature re-
quires extracellular ligand binding to result in a dy-
namic change in receptor conformation that is reflected
in exposure of a signaling domain at the cytosolic sur-
face, which interacts with the classic proximal effecter
partner, a heterotrimeric G protein. However, not only
are these regions of classic function important, but
they also provide their respective regions for the bind-
ing of allosteric ligands from the extracellular space
and the cytosol. In addition, the intramembranous
surfaces of 7TMRs within the plane of the membrane
provide still more sites for possible allosteric action.
These three allosteric vectors, directed toward 1) the
ectodomain, 2) the cytosolic face, and 3) the intramem-
branous faces of 7TMRs (Fig. 1), provide numerous
opportunities for functional selectivity of the action of
drugs (see section V.C.2.c). Such functional selectivity
can even manifest itself differently at the same recep-
tor expressed in distinct cellular environments that
are present not only in different cells in different
organs but even in the same type of cell in a single
organ that might be affected differentially by its local
environment.
This review considers 7TMRs as a means of informa-
tion transfer from the extracellular space to the cytosol.
As will be seen, there is two-way transfer of information
that communicates the state and needs of the cell to the
extracellular space. They do this through a change in
shape, specifically referred to as a change in conforma-
tion. The mechanism by which this occurs is allosterism.
The term allosteric is derived from the Greek word allos,
meaning “else” or “different.” Early ideas about alloster-
ism related to the explanation of how products of enzyme
pathways, structurally unrelated to the substrates,
could influence the activity of some bacterial enzymes
(Umbarger, 1956). Ideas then progressed toward the
postulate that these effects occurred not through mutual
exclusion and steric hindrance of substrate from the
active site but rather through the interaction of mole-
cules at topographical and stereochemically distinct
sites (Changeux, 1961; Monod and Jacob, 1961). The
remoteness of these sites of interaction was suggested by
early discussions of these interactions being “teleo-
1Abbreviations: 101.10, peptide sequence RYTVELA; 5-HT, 5-hy-
droxytryptamine; 6-GNTI, 6-guanidinoaltrindole; 7TMR, seven
transmembrane receptor; A-77636, (1R,3S)-3-(1-adamantyl)-1-
aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran; AD101,
4-[1-(2,4-dimethyl-3-pyridinylcarbonyl)-4-methyl-4-piperidinyl]-2(S)-
methyl-1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine; AMD3100,
1,1-[1,4-phenylenebis(methylene)]bis-1,4,8,11 tetraazacyclotetrade-
cane octahydrochloride; AT, angiotensin; CB, cannabinoid; CCL, che-
mokine; CCR, chemokine; CL316243, (R,R)-5-[2-[[2-(3-chlorophenyl)-2-
hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-decarboxylate;
CP320626, 5-chloro-1H-indole-2-carboxylic acid (1-(4-fluorobenzyl)-2-
(4-hydroxypiperidin-1-yl)-2-oxoethyl)amide; CRTH, chemoattractant
receptor-homologous molecule expressed on TH2 cells; CXCR, chemo-
kine receptor; ERK, extracellular signal-regulated kinase; GLP, gluca-
gon-like receptor; GRK, G protein receptor kinase; HEK, human
embryonic kidney; IL, interleukin; LP1805, N,N-(2-methylnaphthyl-
benzyl)-2-aminoacetonitrile; LY2033298, 3-amino-5-chloro-6-methoxy-
4-methyl-thieno[2,3-b]pyridine-2-carboxylic acid cyclopropylamide;
MAP, mitogen-activated protein; MAPK, mitogen-activated protein ki-
nase; MCP-1, monocyte chemoattractant protein-1; mGluR, metabo-
tropic glutamate receptor; NAM, negative allosteric modulator; NMDA,
N-methyl-D-aspartate; Org27569, (5-chloro-3-ethyl-1H-indole-2-
carboxylic acid [2-(4-piperidin-1-ylphenyl)ethyl]amide); PACAP, pitu-
itary adenylate cyclase-activating polypeptide; PAM, positive allosteric
modulator; PDZ, postsynaptic density 95/disc-large/zona occludens;
PTH, parathyroid hormone; RAMP, receptor activity-modifying mem-
brane protein; RB213, N-(2-adamantyloxy)carbonyl--Me-D-Trp-D-
cis-Hyp-(o,p-dichlorophenol); SB242,084, 6-chloro-5-methyl-1-[6-
(2-methylpyridin-3-yloxy)pyridin-3-ylcarbamoyl]indoline; SCH-C,
(Z)-(4-bromophenyl){1-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-
4-methyl-1,4-bipiperidin-4-yl}methanone O-ethyloxime; SII,
Sar1,Ile4,Ile8-AngII; SKF83959, 6-chloro-2,3,4,5-tetrahydro-3-
methyl-1-(3-methylphenyl)-1H-3-benzazepine-7,8-diol; SP-D,
[D-Arg1,D-Phe5,D-Trp7,8,Leu11]substance P; SP-G, [Arg6,D-Trp7,9,N-
Me-Phe8]substance P(6–11); SR141716, N-(piperidino-1-yl)-5-(4-
chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide;
SR59230A, 3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-
ylamino]-2S-2-propanol oxalate; SSTR, somatostatin receptor subtype 5;
TAK-220, 1-acetyl-piperidine-4-carboxylic acid {3-[4-(4-carbamoyl-benzyl)-
piperidin-1-yl]-propyl}-(3-chloro-4-methyl-phenyl)-amide; TAK-779, ]N,N-
dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-
yl)carbonyl)amino)benzyl)tetrahydro-2H-pyran-4-aminium chloride; TM,
transmembrane; UK-14,304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-
quinoxalinamine; VPAC, vasoactive intestinal polypeptide-pituitary ade-
nylate cyclase-activating polypeptide.
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nomic” (Monod and Jacob, 1961). In biochemical terms,
allosterism relates to a change in shape and activity of a
protein that results from combination with another sub-
stance at a point other than the chemically active site. It
is important to note that allosterism must be defined in
terms of the bodies involved and can change, both in
quality and quantity of effect, for the same protein with
different interactants. It is useful to define alloster-
ism in terms of three interacting species: the modula-
tor, a ligand or protein that binds to a conduit (usually
a protein) that transduces the thermodynamic alloste-
ric energy to a guest, which receives the influence of
the modulator through the conduit (Fig. 2). It should
also be noted that allosteric effects are reciprocal in
that guests impart the same allosteric energy through
the conduit back to the modulator (Tra¨nkle et al.,
1999). In this sense, the roles of modulator and guest
become interchangeable in that the effect of the mod-
ulator on the guest is identical to the effect of the
guest on the modulator. Allosterism is an extremely
important biochemical mechanism (even having been
referred to as the “second secret of life,” second only to
the genome) (Fenton, 2008) because it allows proteins
to sense their environment and react to it. The power
of the mechanism emanates from the ability of the
protein to sense from sites other than the active site or
the site being modulated. Therefore, the active site is
free to function until changes in the environment dic-
tate that a change should occur. As a preface to dis-
cussion of 7TMR function, it is useful to consider their
structure.
II. The Structural Organization of Seven
Transmembrane Receptors
Members of the superfamily of 7TMRs are believed to
have evolved from a common precursor, retaining their
heptahelical architecture and their physical and func-
tional coupling to heterotrimeric G proteins yet being
distributed into families and subfamilies that have dis-
tinctive structural elements and distinctive themes for
ligand binding, receptor activation, and receptor regula-
tion (Kolakowski, 1994; Fredriksson et al., 2003; Ro¨mpler et
al., 2007). Although primary structural information has
been used to divide this superfamily into major families,
tertiary structural information is available for intact
receptors in only one of these families.
There are finally high-resolution three-dimensional
structural data for a few members of the largest group of
7TMRs, representing family A (the rhodopsin/-adren-
ergic receptor family) (Cherezov et al., 2007; Rasmussen
et al., 2007; Rosenbaum et al., 2007; Hanson et al., 2008;
Conduit
Modulator
Guest
FIG. 2. Allosteric systems. Energy is transmitted between loci of bind-
ing for the modulator and that of the guest. Energy transfer is reciprocal
(Tra¨nkle et al., 1999); therefore, the role of modulator and guest are
operationally interchangeable. For an extracellular modulator binding
site, the guest binding site can be extracellular, within the plane of the
membrane, or facing the cytosol.
FIG. 1. Typical topology of 7TMRs. Shown is a representative struc-
ture of a family A 7TMR with a peptide ligand. The extracellular ectodo-
main is shown in the top of the lateral views, whereas the top views
provide appreciation for the helical bundle domain. The cytosolic region is
shown at the bottom of the lateral views. The transmembrane segments
are colored blue to red from amino terminus toward carboxyl terminus of
the receptor. Shown at the carboxyl-terminal end of TM7 is the extension
into another helix 8 that lies adjacent to the cytosolic face of the lipid
bilayer.
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Jaakola et al., 2008; Warne et al., 2008). These have
confirmed many of the de novo structural predictions
and interpretations of lower resolution structures that
had been made previously and have finally provided a
level of molecular detail adequate to explain many phar-
macological observations and many of the general con-
cepts of 7TMR allosterism. This family includes many of
the receptors for biogenic amines and small peptides.
The transmembrane segments of family A 7TMRs con-
tain most of the signature sequences defining this fam-
ily, making it no surprise that the structures of the
helical bundle regions of these 7TMRs seem to be highly
conserved.
7TMR family B has substantially fewer members yet
contains several strong candidates for the development
of potentially important drugs (Harmar, 2001; Hoare,
2005). The natural ligands for these receptors are all
moderately large peptides, such as calcitonin, parathy-
roid hormone, and glucagon, that have diffuse pharma-
cophoric domains. This family of receptors has a charac-
teristic long amino-terminal tail containing six conserved
cysteine residues that contribute to three conserved di-
sulfide bonds that provide structural stability and a
conserved cleft for the docking of the often helical car-
boxyl-terminal region of the peptide ligands (Grace et
al., 2004). This helps to orient the amino terminus of
these peptides, which is critical for biological activity
toward the receptor helical bundle region (Tan et al.,
2006). It is noteworthy that, based on the absence of the
signature sequences from family A and on the conserva-
tion of a distinct set of residues and the polarity of these
residues in family B, the helical bundle of family B
7TMRs is predicted to be structurally distinct from that
of family A 7TMRs (Donnelly, 1997; Tams et al., 1998).
No direct experimental data yet exist to provide insights
into the structure of this important domain of these
receptors.
Family C 7TMRs also have a very large amino-termi-
nal domain, often with a Venus flytrap-like structure
(not found in the orphans in this family), that seems to
play important roles in natural ligand binding (de Vos et
al., 1992; White et al., 1998; Kunishima et al., 2000). The
ligands for these receptors are actually quite diverse,
including large glycoprotein hormones and very small
molecules such as glutamate, calcium, GABA, and some
taste molecules and L--amino acids. The 22 subtypes of
receptors that have been described in this family are
divided into four groups, including 1) the metabotropic
glutamate receptors; 2) the calcium-sensing receptor,
taste receptors, and GPRC6A; 3) the type B GABA re-
ceptors; and 4) orphan receptors. Dimerization is a fun-
damental theme for these receptors, with important
functional impact of homo- versus heterodimerization.
This theme will be discussed in depth below.
Themes for molecular interactions with 7TMRs are
conserved throughout the superfamily, although the de-
tails of some of these themes diverge in individual fam-
ilies. These themes include 1) interactions with the ex-
tracellular face of the receptors, including ligands, both
natural and pharmaceutical (guest allostery); 2) inter-
actions with the cytosolic face of the receptors, including
heterotrimeric G proteins, as well as other key cytosolic
proteins (cytosolic allostery: biased agonism and antago-
nism); and 3) interactions in the plane of the lipid bilayer,
including interactions with other 7TMRs and other mem-
brane proteins (lateral allostery: oligomerization).
A. Structure and Interaction of Ligands with Seven
Transmembrane Receptors
1. Interaction of Seven Transmembrane Receptors with
Natural Ligands. The mode of natural ligand binding
and the structures of the ligands correlate with positions
within the proposed minimally plausible phylogenetic
tree of 7TMR evolution (Kolakowski, 1994). In fact, the
position within this tree has often been the best clue to
the identity of the natural ligand that recognizes a par-
ticular orphan receptor. Family A contains rhodopsin
and many of the biogenic amine receptors in which the
natural ligands typically dock within the helical bundle
at the level of the lipid bilayer (Ji et al., 1998). This
family also includes a large number of receptors that
bind peptide ligands, particularly those having a focused
pharmacophoric region at the carboxyl terminus of the
ligand. Such ligands typically have binding determi-
nants closer to the outside surface of the plasma mem-
brane, often with contributions of external loop and tail
regions of their receptors, although some have been pos-
tulated to dip into the helical bundle. The greatest de-
gree of similarity among family A 7TMRs resides within
their transmembrane segments. Indeed, three regions of
these receptors that have been postulated to play critical
roles in the conformational changes in these receptors,
are associated with their activation, and have been iden-
tified as “microswitches” are within these segments
(Nygaard et al., 2009). These include Trp6.50 (the W in
the CWxP motif in TM6) at the bottom of the major
intrahelical ligand-binding pocket, Tyr7.53 (the Y in the
NPxxYmotif inTM7) that is believed to connect thebottomof
TM7 and helix 8 at the cytosolic surface of the lipid
bilayer, and Arg3.50 (the R in the D/ERY motif at the
bottom of TM3) at the cytosolic face of TM3, where it
probably interacts with the G protein. These are postu-
lated to contribute to an extended set of toggle switch
movements that link ligand binding to a region accessi-
ble from the extracellular milieu to conformational
changes that facilitate protein-protein interactions at
the cytosolic interface and result in intracellular signal-
ing events.
An allosteric molecule such as a 7TMR is capable of
assuming multiple conformations, some of which may be
“active” (i.e., facilitating the coupling or association with
a molecule that initiates a signaling cascade) (Kobilka
and Deupi, 2007). Some of the conformations are clearly
inactive and may be pharmacologically silent. It is pos-
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sible that only a subset of conformations will interact
with naturally occurring regulatory molecules. There is
an equilibrium between the dynamic conformations of
7TMRs, with many “locked” into inactive, nonsignaling,
low-energy states, whereas some are capable of consti-
tutive activity, reflecting assumption of an active con-
formation for at least a portion of the time (Kobilka and
Deupi, 2007). The “microswitches,” we are beginning to
understand, are likely to play important roles in protect-
ing the receptor from the classic active conformation
when they are in the “off” position and in stabilizing this
conformation when they are in the “on” position (Schwartz et
al., 2006). As we understand more about allosteric li-
gands, it is likely that they, too, will be discovered to
stabilize a variety of conformations, ranging from the
“full on” conformation (which may be typical of a full
allosteric agonist), to “variant partially on” conforma-
tions (which may be typical of biased agonists or alloste-
ric modulators), and to “off” conformations (which may
be typical of allosteric inhibitors). It is particularly in-
teresting that there are examples where even natural
ligands might express differential functional profiles at
a naturally occurring receptor (Picchio et al., 2008; Mox-
ley et al., 2009) (see section V.C.2.c), as was first de-
scribed for CCL19/CCL21 at the CCR7 receptor (Kohout
et al., 2004). Although the specific structural basis for this
is not yet clear, it is consistent with the notion that these
ligands stabilize distinct active conformations that facili-
tate different patterns of proximal effector interactions.
For many years, the prototypical 7TMR structure was
based on rhodopsin, for which there was biochemical and
biophysical data, including the only high-resolution
crystal structure (Palczewski et al., 2000). Since 2000, a
number of inactive, dark-state crystal structures of var-
ious states of bovine rhodopsin and thermostable mu-
tants have been reported (Okada et al., 2004; Standfuss
et al., 2007). Since 2007, two different structures of the
2-adrenergic receptor, the 1-adrenergic receptor,
squid rhodopsin, and the adenosine A2a receptor bound
to antagonists were reported (Cherezov et al., 2007; Ras-
mussen et al., 2007; Rosenbaum et al., 2007; Hanson et
al., 2008; Jaakola et al., 2008; Warne et al., 2008). All of
these have highly similar helical bundles, whereas the
loop and tail regions were quite divergent. These struc-
tures also highlight a major funnel-shaped intrahelical
ligand-binding pocket, and extracellular loop 2b sits
above the entry, perhaps playing a gating role (Nygaard
et al., 2009).
It was only in 2008, when a crystal structure was
solved for opsin associated with a carboxyl-terminal pep-
tide fragment of its G subunit, transducin, that the first
minimally active conformation of a family A 7TMR could
be directly appreciated (Scheerer et al., 2008). This
structure suggested the presence of a substantial change
in the arrangement of the helical bundle, with promi-
nent movement of TM6. Clearly, it will be critical to
elucidate additional active structures of these receptors
in the future.
Indeed, analogous insights have come from an in silico
molecular modeling analysis of inactive and predicted
active structures of the 2-adrenergic receptor (Katritch
et al., 2009). In this work, the authors used a powerful
energy-based computational approach directed by li-
gand structures and complemented by mutagenesis data
to gain insights into the activation mechanism for this
family A 7TMR. In this report, the authors predict an
activation mechanism that is accompanied by tilting of
the extracellular portion of TM5 toward the receptor
axis. This movement is shown to facilitate interaction of
the full and partial agonist ligands with this receptor,
with the ligand tail interacting with side chains of
Asp113 and Asn312 and the ligand head interacting
with side chains of Ser203, Ser204, and Ser207. The
kinetics of achieving the active conformation are sup-
ported by two fast steps, representing agonist fit into a
loose binding pocket and conformational changes facili-
tating full engagement in the binding pocket, and a slow
step representing more substantial movements and de-
formations of the transmembrane helices.
The natural ligands for family B 7TMRs are all mod-
erately large peptides with diffuse pharmacophoric re-
gions, the amino terminus of the peptides playing im-
portant roles in receptor activation (Ulrich et al., 1998).
This is quite distinct from peptide ligands for family A
7TMRs. Sequence and conservation analysis of the pre-
dicted transmembrane segments of family B 7TMRs has
suggested a very different structure than that present in
family A 7TMRs (Donnelly, 1997; Tams et al., 1998). The
longer amino-terminal tail region of family B 7TMRs is
quite conserved, including the presence of six cysteines
and three disulfide bonds, and structure-activity, mu-
tagenesis, and photoaffinity labeling studies have all
supported an important role of this region in natural
ligand binding. Indeed, recent solution of NMR and crys-
tal structures of amino-terminal domains of several fam-
ily B 7TMRs, including ligand-associated states, has
confirmed this and has provided some insights into the
mode of ligand binding (Grace et al., 2004, 2007;
Parthier et al., 2007; Sun et al., 2007a; Pioszak and Xu,
2008; Pioszak et al., 2008; Runge et al., 2008).
The characteristic structure of the amino-terminal re-
gion of family B 7TMRs includes two antiparallel
-sheets, three disulfide bonds, an amino-terminal -he-
lix, and multiple loop regions. The carboxyl-terminal
regions of the natural peptide ligands for these receptors
that are often in helical structures are believed to occupy
a hydrophobic binding cleft between the amino-terminal
-helix and loop structures. Although there are minor
differences in the docking of these ligands in the NMR
and crystal structures relative to predictions coming
from other types of experimental constraints, such as
photoaffinity labeling, the theme of docking in this re-
gion has been quite consistent. Unfortunately, the ori-
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entation of the receptor amino terminus relative to the
helical bundle of the family B 7TMRs is unknown, and
there are not yet adequate constraints to guide this
process. Here, unlike the relative consistency of predic-
tions for site of peptide docking, the predictions for do-
main orientation are radically different and diverse—
even the face of the amino-terminal domain that is
directed toward the helical bundle varies from model to
model. Additional experimental constraints (or an intact
receptor structure) clearly will be necessary to advance
this field.
Family C 7TMRs also have large amino-terminal do-
mains that are quite important in natural ligand bind-
ing. Here, crystal structures of this region have nicely
defined structures and mode of ligand binding (de Vos et
al., 1992). The Venus flytrap domain contains two glob-
ular domains arranged as a central -sheet flanked on
both sides by -helices, connected by a hinge region with
a central cleft. This domain is often situated above a
cysteine-rich domain of unknown function that connects
it to the transmembrane helical bundle domain. The
cysteine-rich domain contains nine conserved cysteines
that form four intradomain disulfide bonds and one di-
sulfide bond directed to the Venus flytrap domain. The
disulfides seem to be critical for function and are be-
lieved to add a degree of rigidity to the structure. It is
noteworthy that constitutive dimerization of the family
C 7TMRs has been the theme. The type B GABA recep-
tor and the taste1 receptors in this family exist as het-
erodimers, composed of two distinct structures, whereas
the calcium-sensing receptor and the metabotropic glu-
tamate receptors form homodimers. The latter are quite
interesting in that the homodimeric structures are es-
tablished by both covalent and noncovalent interactions.
The inter-receptor disulfide bond is located in a loop of
the Venus flytrap domain. One large protein ligand can
span both protomers of this dimeric amino-terminal
structure. Here in family C 7TMRs, as in family B
7TMRs, we have little information about the structure of
the helical bundle region. However, there has at least
been consistency in the proposed orientation of the amino-
terminal and helical bundle domains for this family.
In summary, essentially all 7TMRs follow the struc-
tural theme of possessing seven transmembrane helical
segments that arrange in a bundle in the lipid bilayer.
Most of these couple with heterotrimeric G proteins as
the dominant physiological effector pathway. Three ma-
jor families within this superfamily follow distinct struc-
tural themes that even include predicted differences in
the structures of the seven-helix bundle. Each family
follows its unique themes for types of natural ligands,
mechanisms of activation, and importance of interaction
with other endogenous proteins within the cell.
2. Interaction of Seven Transmembrane Receptors with
Drugs. Interactions with pharmaceutical ligands (drugs)
follow few rules, requiring only the presence of “drug-
gable pockets” within the receptors to provide adequate
binding energy to stabilize the drug-receptor complex.
Here, the diversity of the 7TMR families and their struc-
tures and themes for natural ligand binding provide
many options for drug action. All the families are likely
to provide the opportunity for small-molecule ligand
binding within the helical bundles. For many family A
7TMRs, that also represents the orthosteric natural li-
gand binding pocket, whereas for others, this is an allo-
steric binding pocket. There are examples of use of this
docking site for agonists, partial agonists, and antago-
nists. The theoretical advantages of allosteric ligands
have been extensively reviewed recently (Kenakin, 2004,
2007; Leach et al., 2007; Schwartz and Holst, 2007). It is
interesting that all the concepts of allosteric modulation
are also likely to be relevant to regions of the receptors
where there are no distinct “pockets.” Examples of this
are the effects that have been attributed to lipid micro-
environments of the receptor. Although this has not
been studied in great detail, many observations support
variations in signaling based on such interactions with
the intramembranous faces of 7TMRs (Harikumar et al.,
2007, 2008; Gao et al., 2009).
For family A 7TMRs, there are now many examples of
small-molecule drugs with a broad spectrum of activi-
ties. Detailed insights into molecular mechanisms of
binding exist for a limited number of these drugs, par-
ticularly those docking within the structurally con-
strained helical bundle. There is clear evidence for some
of these small molecules to dock closer to or even at the
surface of these receptors (Ji et al., 1998). In general, as
the site of docking of such ligands moves toward the
surface to include external loop and tail regions of the
receptors, our understanding of the molecular basis of
this process becomes less well defined. This probably
reflects the great diversity of structures of these less-
well defined regions and their greater degrees of struc-
tural freedom. Essentially all such ligands for family A
7TMRs that we currently understand bind within a fun-
nel-shaped region with its apex within the helical bun-
dle. There are two relatively well defined pockets in
these receptors that are established by the confluence of
TM3 with TM2, TM6, and TM7 (shallow pocket), and
that of TM3 with TM4, TM5, and TM6 (deeper pocket)
(Schwartz, 1994).
The opportunities for distinct “druggable” pockets in
family B and family C 7TMRs seem to be greater, re-
flecting the larger size and conserved structural com-
plexity of the amino-terminal domains of those recep-
tors. Although the amino-terminal regions of these
receptors are larger than thpse of family A receptors,
providing more opportunities for sites of binding, it may
also be more challenging to elicit and stabilize a relevant
conformational change by binding a small molecule to
such regions. Antagonists targeting such regions may be
easier to develop than agonists. Given what we believe
we understand about the structure-activity consider-
ations and docking of natural peptide ligands to family B
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7TMRs (Hoare, 2005), the binding cleft in the amino
terminus of the receptor that interacts with the carboxyl-
terminal region of the peptides is probably a prime tar-
get for small-molecule antagonist docking (Grace et al.,
2007). Likewise, once we understand the region of these
receptors that interacts with the amino-terminal end of
the natural peptide ligands (postulated to be somewhere
within the second or third extracellular loop regions),
this should provide a fertile site for the action of a broad
range of ligands. There is theoretical reason to believe
that these can range from blocking antagonists to mim-
icking full or partial agonists. This still leaves the helical
bundle region for allosteric drug action at these recep-
tors. In addition, recent data suggest that the “hinge”
region linking the amino-terminal domain and the heli-
cal bundle domain of these receptors may also contain a
“druggable” pocket that can have agonist activity (Dong
et al., 2009). The structural details of this region are still
poorly defined.
In summary, each family of 7TMRs has its own unique
mode of natural ligand binding that reflects its unique
structure. Although this represents the binding of ortho-
steric ligands, there are many opportunities for the bind-
ing of allosterically active drugs. Each 7TMR family
provides several opportunities for the development of
allosteric modulators.
III. Receptor Conformation as
Protein Ensembles
Theoretical modeling (Crozier et al., 2003; Spijker et
al., 2006) and experimental data [Gether, 2000 (i.e.,
site-directed spin labeling, site-directed fluorescence
quenching, sulfhydryl accessibility, disulfide cross-link-
ing); see methods reviewed in Meng and Bourne, 2001;
Hubbell et al., 2003; Kobilka, 2002; Park et al., 2008]
show that receptor proteins exist as collections (termed
“ensembles”) of tertiary conformations. The differences
in these conformations need not be large. For example,
changes of as little as 1 Å can lead to profound effects on
the activity of enzymes and receptors (Koshland, 1998).
Receptors sample these conformations (i.e., roll on a
funnel-shaped “energy landscape”) (Frauenfelder et al.,
1988, 1991; Woodward, 1993; Dill and Chan, 1997;
Hilser and Freire, 1997; Miller and Dill, 1997; Hilser et
al., 1998, 2006; Freire, 1998; Ma et al., 2002) according
to changes in the thermal energy in the system. Thus,
proteins are dynamically fluctuating macromolecules
constantly changing conformations (described as “breathing”
by Englander and Kallenbach, 1983) and taking confor-
mational excursions away from a canonical native struc-
ture (Liu et al., 2006a,b). This dynamic view of proteins
is supported by computer simulations and NMR data
(Volkman et al., 2001; Ikeguchi et al., 2005; Bahar et al.,
2007; Henzler-Wildman et al., 2007) or electron para-
magnetic resonance (Blackburn et al., 2009). In terms of
the number of states sampled by a protein, early models
of two discrete protein states (Monod et al., 1965) have
been extended to models describing thermal fluctuations
over a continuum of states (Kotani, 1968). In fact, there
are probably a vast number of conformations associated
with energy wells in the landscape and thus are fre-
quented more often than random chance in the normal
course of conformational sampling. Moreover, the bot-
tom of the energy wells are probably “rugged,” allowing
for a range of nearly isoenergetic conformers; the more
flexible is the protein, the larger the ensemble of con-
formers (Kumar et al., 2000). The energy wells relate to
the population times spent in each conformation; a high
population time would correspond to a conformation
that the protein commonly adopts, whereas a low popu-
lation time would correspond to a relatively rare confor-
mation. Because allostery involves changes in protein
conformation, the ability of a protein (receptor) to take
on new conformations is related to the ability of the
protein to be allosterically modulated. Therefore, a pro-
tein with an already rigid structure is less inclined to be
allosterically modulated than a protein with a high de-
gree of intrinsic disorder. Thus, there must be a balance
between thermodynamic stability to support specificity
(Janin and Wodak, 1983; Frauenfelder, 1989; Gerstein
et al., 1994) and flexibility to mediate conformational
change to catalyze biochemical reaction pathways (Live-
say et al., 2004). Molecular dynamics has been used to
determine that signaling proteins have an unusual
amount of intrinsic disorder, making them ideal candi-
dates to be allosterically modulated (Liu et al., 2006b;
Hilser and Thompson, 2007). As stated by Mittag and
Forman-Kay (2007), “… all states that are accessible to
proteins, whether they contain stably folded globular
structure, stretches of transiently populated structural
motifs or little structure, are likely to be exploited by
living cells for some function.” If a conformation leads to
a defined cytosolic outcome (i.e., second messenger pro-
duction, internalization, phosphorylation, binding of cy-
tosolic protein) then it may be operationally defined as
an “active state.” The biological activities controlled by a
given receptor will be mediated by the energy-weighted
contributions of the component microstates of the en-
semble (Hilser et al., 2006). Thus, there could be ensem-
bles for a number of cellular functions modulated by the
receptor (Kenakin, 2002b). A reasonable model for li-
gand interaction with such a system describes differ-
ential binding to the various states; the greater the
affinity a ligand has for a particular state, the greater
the binding.
In summary, a collection of receptor proteins should
be thought of as a dynamic system of interchanging
conformations, not a single static tertiary conformation.
The ability of a given protein to change conformation
may be linked to its ability to be allosterically modulated
and also to induce a cellular response through binding to
cytosolic signaling proteins.
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IV. Allosteric Transitions within
Receptor Ensembles
To understand the interaction of molecules with var-
ious receptor conformations, it is useful to discuss mech-
anisms of interaction of molecules with protein ensem-
bles. Two extreme views are embodied in the concepts of
“conformational induction” and “conformational selec-
tion.” Induction is a product of the 50-year-old concept
proposed by Koshland (1958), wherein the molecule con-
tributes energy to cause a change in the conformation of
the receptor. Conformational selection is rooted in the
“population shift” model emanating from the Monod-
Wyman-Changeux model of allostery (Monod et al.,
1965) whereby molecules selectively bind to pre-existing
conformations to stabilize them and thus bias the sys-
tem toward a predominance of those conformations
(Bosshard, 2001; James and Tawfik, 2003). Conforma-
tional induction and selection can be viewed in terms of
jumps on dynamic energy landscapes for receptors.
Thus, a receptor may have a canonical low-energy con-
formation and somewhat higher energy “active state”
conformation. For both mechanisms, binding of the li-
gand causes the active state to become the preferred
low-energy state. In terms of the conformational selec-
tion hypothesis, there is a small probability that the
receptor pre-exists in the active state without ligand
bound. The ligand binds to this conformation, thus sta-
bilizing it and driving the equilibrium toward a more
stabilized active state. Within the conformational induc-
tion scenario, the ligand binds to the low-energy inactive
state of the receptor to cause a conformational change in
the protein to the active state. Molecular simulations
favor conformational shift models for the binding of
small molecules to proteins (in pharmacological terms,
drug-like molecules to receptors) (Okazaki and Takada,
2008). It should be noted that a selection of a relatively
rare pre-existing conformation would thermodynami-
cally resemble induction (Kenakin, 1996). For example,
kinetic experiments for glutathione transferase (Stella
et al., 1998; Nieslanik et al., 1999) and ester hydrolyzing
antibodies (Geyer et al., 1996; Lindner et al., 1999) show
that what was considered conformational induction was
equally consistent with pre-existing equilibria between
high- and low-affinity conformations.
Conformational selection was proposed by Burgen
(1981) to account for pharmacological efficacy of mole-
cules acting on drug receptors. Specifically, biologically
active molecules bind selectively to certain receptor con-
formations that mediate physiological activity (so called
active conformations) and thus enrich their presence in
the ensemble (Burgen, 1981). This process, articulated
as Le Chatelier’s principle, leads to enrichment of the
preferred conformations at the expense of others (i.e., if
a dynamic equilibrium is disturbed by changing the
conditions, the position of the equilibrium moves to
counteract the change). The various members of the
stabilized ensembles may or may not have distinct bio-
logical activity (Onaran and Costa, 1997; Onaran et al.,
2000). If they interact with cytosolic signaling proteins,
then a unique direct signal may be obtained from ligand
binding; this will be discussed specifically in section V.C.
The resulting stabilized conformation may have no in-
teraction with cellular proteins but may change the be-
havior of the receptor toward another ligand; this falls
under the classification of classic guest allostery (see
section V.A).
A traditional view of allosteric linkage has proposed
specific pathways that link the allosteric modulation site
with the guest (substrate, endogenous ligand) binding
site, in effect an energetic “hot wire” joining the sites
(Lockless and Ranganathan, 1999; Datta et al, 2008)
(Fig. 3, left). This view is now largely supplanted by a
more general view involving population dynamics relat-
ing allosteric effect to order/disorder transitions to me-
diate long range allosteric communication (Liu et al.,
2006a). Within this latter idea, the coupling between
sites depends upon the intrinsic stabilities of the do-
mains and the interactions between them, which, in
turn, depend upon probability distributions resulting
from the conformational energies within the receptor
protein. Thus, the energy balance within the protein
(i.e., which receptor states are most stable and which
states bind ligand) and not a mechanical link between
sites mediates the energetics of allosterism (Hilser and
Thompson, 2007). Although stabilization of conforma-
tions usually is the cause of the existence of allosteri-
cally distinct states, even thermal energy can cause al-
losteric modulation through changes in domain stability
(Cooper and Dryden, 1984; Popovych et al., 2006). There
is evidence to suggest that the binding of ligands to
protein ensembles reduces motion (Park et al., 2008).
Allosteric “Hot Wire” Global Allosteric Modulation
FIG. 3. Two proposed modes of allostery. The allosteric “hot wire”
proposes a preferred energy link between an allosteric binding site and
the guest site; in the past, this has been an assumed mechanism.
Global allosteric modulation predicts that changes at the guest allo-
steric site are part of global conformational variations within an
ensemble of conformations.
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For example, there is a significant reduction in confor-
mational heterogeneity of the protein Sem-5 upon bind-
ing of its peptide ligand (Ferreon and Hilser, 2003). This
is consistent with the notion that exposure of certain loci
on 7TMRs to G proteins initiates interaction and that
the inactive state of the receptor is a closed conformation
shielding these sites from the cytosol. Consistent with
this notion is the fact that an eleven-amino acid peptide
sequence from the C-terminal region of the third intra-
cellular loop of the -adrenoceptor (Thr284–Thr291) has
the ability to initiate Gs-mediated adenylate cyclase ac-
tivation in turkey erythrocytes (Mu¨nch et al., 1991). In
general this suggests that the special conformations
(i.e., those that shield active sequences of the 7TMR
from cytosolic protein binding) are the inactive (closed)
conformations. Circumstantial evidence for this comes
from mutation studies. For example, point mutation at
position 293 of 1B-adrenoceptor with 22 different amino
acids yields 22 mutants, all of which demonstrate con-
stitutive activity for inositol phosphate production (i.e.,
they are active states) (Kjelsberg et al., 1992). This sug-
gests that there are a number of active states for 7TMRs
that are associated with disorder and relatively fewer
inactive states.
A useful idea to describe the new behaviors assigned
to an allosterically modulated receptor is to consider
that ligand binding essentially moves the receptor onto
another energy landscape (Peleg et al., 2001). Within
this idea, the native and allosteric ensembles have glo-
bally distinct conformations (Fig. 3, right) and many
other regions of the receptor proteins may differ in ad-
dition to the binding sites for the modulator and guest.
This idea is supported by the ability of allosteric modu-
lators to cause disruption of the interactions of huge
proteins that bind to each other at numerous loci. For
example, mutation and structural data suggest that the
CCR5 chemokine receptor and HIV-1 viral coat binding
protein gp120 interact at numerous points in the fusion
and subsequent viral infection process (Atchison et al.,
1996; Doms and Peiper, 1997; Doranz et al., 1997; Picard
et al., 1997; Rucker et al., 1997). This situation is not
readily amenable to blockade through steric interaction
of small drug-like molecules. The low molecular weight
drug-like inhibitors that block HIV-1 entry have been
shown to do so through an allosteric mechanism
(Watson et al., 2005; Muniz-Medina et al., 2009); this, in
turn, is consistent with a global change in CCR5 confor-
mation to interfere with numerous regions of interaction
between CCR5 and gp120.
In terms of the relative geography of binding of mod-
ulators and guests, there is a wide range of distances
between these in various proteins. For example, the
binding site for 5-chloro-1H-indole-2-carboxylic acid (1-(4-
fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)amide
(CP320626) for glycogen phosphorylase b is 33 Å from
the catalytic site and 15 Å from the site for cyclic AMP
(Oikonomakos et al., 2000). If it is accepted that a
direct connection (i.e., “hot wire”) between the sites
need not exist, then there is no limitation as to the
distance between energetically linked allosteric and
active sites on receptors. It is intuitively simple to
understand how an allosteric modulator could have
different effects on different guests (probe depen-
dence) if those guests bind in different regions of the
protein; this will be referred to as “multiple-site guest
allostery” (Fig. 4A). For example, experiments with
chimeric CCR-5 chemokine receptor and HIV-1 entry
inhibitors have shown that portions of CCR5 that
interact with the endogenous chemokine agonist mac-
rophage inflammatory protein type 1 differ from
those that interact with HIV-1 gp120 (Blanpain et al.,
1999a,b; Howard et al., 1999). Likewise, there is evi-
dence to suggest that the peptide chemokine CCL5
binds to regions of the receptor different from those
that bind one of these, namely the HIV entry-inhibitor
Sch-C (Wu et al., 1997; Blanpain et al., 2003; Tsamis
et al., 2003). Thus, binding at an allosteric site pre-
sumably stabilizes an ensemble of conformations, the
members of which may have regions of the protein
considerably different from the native ensemble. In fact,
it has been shown that mutation in regions of receptor
proteins can cause dramatic changes in the overall con-
formation of the protein (Gekko et al., 2004; Lu et al.,
2005). From this standpoint, it might be expected that a
conformational change in one region of the receptor
would rarely if ever be linked to the same conforma-
tional change in another portion of the receptor.
In addition to multiple guest allostery, it also is common
to observe different allosteric effects emanating from inter-
actions at a common modulator binding site (Fig. 4B). The
classic example of this is the effects of muscarinic receptor
alkyltrimethylammonium agonists in guinea pig ileum,
which provided the basis for the concept of agonist efficacy.
Specifically, R. P. Stephenson (1956) showed that a very
similar series of molecules, which presumably bound to the
same loci on the muscarinic receptor, nevertheless had
very different abilities to produce muscle contraction (Fig.
4B). On the basis of these data, the concept of agonist
efficacy was proposed; i.e., though the molecules presum-
ably bound to the same site on the receptor, the way they
bound produced different effects on the receptor. Nuances
in agonist binding to a common site have been observed
with computational, X-ray and binding methods (Hogner
et al., 2002; Bhattacharya et al., 2008). The activation of
7TMRs by agonists is an allosteric system consisting of a
modulator (agonist) interacting with a conduit (receptor) to
affect a guest (G protein). Conventional guest allostery
(modulator affecting the binding of another ligand or pro-
tein as a guest) is identical only what is referred to as
efficacy for cellular response is generally referred to as
cooperativity in guest allosteric systems. However, the fact
that several different allosteric modulators can bind to the
same allosteric site but produce very different effects is
still true. For example, structurally very diverse alloste-
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ric modulators of CCR5 [aplaviroc, maraviroc, vicriviroc,
N,N-dimethyl-N-(4-(((2-(4-methylphenyl)-6,7-dihydro-
5H-benzocyclohepten-8-yl)carbonyl)amino)benzyl)tetra-
hydro-2H-pyran-4-aminium chloride (TAK-779), and
1-acetyl-piperidine-4-carboxylic acid {3-[4-(4-carbamoyl-
benzyl)-piperidin-1-yl]-propyl}-(3-chloro-4-methyl-
phenyl)-amide (TAK-220)] have all been shown to bind
to a single allosteric site on the CCR5 receptor (Maeda et
al., 2006; Kondru et al., 2008). However, mutagenesis
studies showed that each of the modulators displayed a
unique interaction profile with the amino acids in the
binding pocket. Similar data have been shown for the
CCR5 modulators TAK-779, 4-[1-(2,4-dimethyl-3-
pyridinylcarbonyl)-4-methyl-4-piperidinyl]-2(S)-methyl-
1-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]piperazine
(AD101), and (Z)-(4-bromophenyl){1-[(2,4-dimethyl-1-
oxido-3-pyridinyl)carbonyl]-4-methyl-1,4-bipiperidin-
4-yl}methanone O-ethyloxime (SCH-C) (Seibert et al.,
2006).
In summary, a ligand can be thought to enter a col-
lection of interchanging protein conformations (a “con-
formational cafeteria”) and through a process of confor-
mational selection, stabilize select conformations at the
expense of others. These stabilized conformations may
have pharmacological function, thereby linking the li-
gand-receptor binding process to a pharmacologic re-
sponse (efficacy). Ligands may stabilize global conforma-
tions through binding at sites distal from the sites
binding signaling proteins and endogenous hormones
and neurotransmitters. Finally, binding of different li-
gands in different ways to a common site can lead to
different allosteric consequences for the receptor (differ-
ing ligand efficacies).
V. The Vectorial Nature of Allostery
In a protein ensemble world, the ramifications of mod-
ulator binding to receptor protein have no boundary and
allosteric effect can be exerted throughout the protein. It
is useful to consider these effects as a vector of energy,
because this allows both the classification and unifica-
tion of allostery for documented effects of ligands on
7TMRs. Therefore, considering a molecule as the modu-
lator acting on the 7TMR conduit protein, the vector can
A  Multiple-Site Guest Allosterism
B  Single-Site Guest Allosterism
100
90
80
70
60
50
40
30
20
10
0
HIV-1 CCL5
%
 B
in
di
ng
60
50
40
30
20
10
0
%
 M
ax
im
al
 C
on
tr
ac
tio
n
CCL5 HIV-1
Agonist
Alpaviroc
G
FIG. 4. Classification of allostery on the basis of number of sites. A, multiple site allostery involves the interaction of more than one guest with the
modulator. Probe dependence results in different effects on each guest for a given modulator. The example shown shows the effect of the CCR5
modulator aplaviroc on CCL5 (no effect on binding) and HIV-1 (complete inhibition of binding) (Watson et al., 2005). B, probe dependence can also
result from the interaction of different modulators at the same modulator binding site for the same guest. The different abilities of alkyltrimethyl-
ammonium compounds to initiate contraction of guinea pig ileum as mediated by G protein binding is a classic example (Stephenson, 1956). Both the
modulator(s) and G proteins bind at a single site.
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be described in terms of the location of the guest. Thus,
if the guest is another ligand cobinding with the modu-
lator, this will be referred to as classic guest allostery
(Fig. 5). If the guest interacts with the conduit along the
plane of the membrane [either another receptor as re-
ceptor oligomerization or auxiliary protein, such as a
receptor activity-modifying membrane protein (RAMP)],
this will be referred to as laterally directed allostery
(Fig. 5). Finally, if the guest resides in the cytosol, then
modulators can cause alteration of cellular function; i.e.,
all 7TMR agonists are allosteric modulators. There are
new data to show that these effects are considerably
more complex than described previously, leading to a
phenomenon referred to as functional selectivity or bi-
ased agonism or antagonism. This will be discussed un-
der the heading of cytosolic allostery (Fig. 5) (see section
V.C.2).
A. Classic Guest Allosterism
The awareness of allosteric ligands has increased
sharply over the past decade. This is consistent with the
change in screening strategies in industry for new mol-
ecules. Specifically, to detect biological activity in large
libraries of molecules, a robust, rapid, robotically friendly
screening format must be used; until recently, this has
been radioligand binding, which is biased toward detect-
ing orthosteric effects. Technology now is providing
rapid robust screening methods in formats that detect
biological function, and with this change in screening
has come an increase in the number of allosteric mole-
cules discovered (Rees et al., 2002). Allosterism is clearly
powerful and is an obvious mechanism for natural con-
trol of physiological systems. Although several examples
of feedback inhibition of enzymes are known (Roberts et
al., 1955; Pardee and Yates, 1956; Umbarger, 1956), it is
still surprising that there are so few known natural
allosteric modulators in the body. However, on the other
hand, because allosteric modulators are usually struc-
turally dissimilar to endogenous ligands, it would be
difficult to identify natural modulators within the myr-
iad of natural peptides present in the body (Lindsley and
Rutter, 2006). At present, only a few natural allosteric
modulators are known. For example, an unnatural D-
amino acid, D-serine formed in the brain by serine race-
mase is a potent allosteric modulator of the N-methyl-
D-aspartate (NMDA) receptor (Tsai and Coyle, 2002).
Likewise, the calcium receptor is activated allosterically
(enhanced sensitivity to Ca2) by several classes of L-
amino acids including L-phenylalanine and L-trypto-
phan (Lee et al., 2007). Another natural allosteric mod-
ulator initially purifed from rat brain is the tetrapeptide
Leu-Ser-Ala-Leu (LSAL; later named 5-HT moduline),
which selectively reduces the binding of 5-HT to the
5-HT1B receptor (Massot et al., 1996; Rousselle et al.,
1996).
1. Unique Properties of Allosteric Modulators. Feed-
back studies on the effects of enzyme products on the
rate of enzyme reactions were among the earliest explo-
rations of allosteric mechanisms. Within this scenario,
the binding of a molecule (modulator) to an allosteric
site on the protein leads to a change in behavior of the
protein toward the binding of another molecule (guest)
at a different site. This change in behavior can be an
inhibition or potentiation of effect of the guest. If the
guest is a pharmacologically active agonist (with affinity
and efficacy), then the affinity and efficacy of that mol-
ecule can be affected in different ways. Allosterism is a
powerful mechanism that can induce powerful changes
in receptor behavior; several reviews describing alloster-
ism in receptors and allosteric molecules have been writ-
ten (Christopoulos, 2002; Christopoulos and Kenakin,
2002; Goudet et al., 2004; Noeske et al., 2006; Kenakin,
2007a; Leach et al., 2007; May et al., 2007; Conn et al.,
2009a). It is useful to consider some general properties
of guest allostery as they pertain to the therapeutic
profiles of drugs.
Allosteric modulators, by virtue of the fact that they
may stabilize different global conformations of the re-
ceptor, have the potential to disrupt protein-protein in-
teractions of very large proteins. As discussed previ-
ously, the multiple contacts between the chemokine
receptor CCR5 and HIV-1 viral coat protein gp120 can
be successfully blocked by small-molecule allosteric
modulators, leading to an effective prevention of HIV-1
entry and subsequent progression to AIDS. In theory,
orthosteric antagonist ligands have the potential to do
the same for guest molecules removed from the ortho-
steric binding site (i.e., inverse agonists for the binding
site for G proteins). However, this is also an allosteric
effect in that the “orthosteric” antagonist actually be-
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FIG. 5. The vectorial nature of 7TMR allostery. Modulators can affect
binding and function of other ligands cobinding to the receptor (classic
guest allostery); of the cobinding of other proteins along the plane of the
membrane (other receptors or membrane-binding proteins such as
RAMPs); or of cytosolic signaling proteins, such as G proteins or -arres-
tin. These effects can be simultaneous and all emanate from the same
mechanism(s) of allosteric change within the conduit 7TMR protein.
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comes an allosteric modulator for the guest molecule G
protein as the receptor changes shape according to en-
ergy constraints put on the molecule through binding of
the orthosteric antagonist. A distinction must be made
between orthosteric effects where the antagonist steri-
cally hinders the access of the agonist to its binding site
and any other change in conformation that results from
the binding of the orthosteric antagonist to the receptor,
such as stabilization of the inactive receptor state for
inverse agonists.
A unique feature of allosteric modulators, with respect
to guest ligand binding, is the fact that both the modu-
lator and guest can bind simultaneously to the receptor
protein. In fact, the interaction between these two li-
gands occurs through a change in conformation of the
conduit protein (receptor). This gives allosteric modula-
tors their three characteristic and unique properties:
saturability of effect, probe dependence, and differential
modulation of ligand affinity and efficacy. Thus, alloste-
ric modulators are permissive with respect to the behav-
ior of the receptor (Kenakin, 2005); this is in contrast to
orthosteric ligands, which have a pre-emptive behavior.
In this latter case, once the antagonist occupies the
receptor, the agonist cannot. The permissive nature of
allosteric interaction is depicted in early models of re-
ceptor allosterism (Stockton et al., 1983; Ehlert, 1988)
(Fig. 6). The receptor may cobind a probe ligand (in
functional studies, this is an agonist; in binding studies,
a radioligand) denoted [A] in the figure and a modulator
(denoted [B]). Both the probe-receptor complex ([AR])
and the ternary complex ([ABR]) can have pharmacolog-
ically relevant behaviors (i.e., may produce response).
The ABR complex has three potential behaviors, relative
to the AR complex made naturally when the modulator is
not present. These behaviors are antagonism [allosteric
antagonists are also referred to as negative allosteric mod-
ulators (NAMs); potentiation of response, positive alloste-
ric modulators (PAMs)] and direct allosteric agonism.
In preparation for discussion of properties of allosteric
systems, it is useful to define two general cooperative
effects of modulators on 7TMRs. Considering agonism,
the agonist will have an affinity for the receptor and also
a value for intrinsic efficacy defining the power of that
agonist to induce a defined response. These affinities
and efficacies themselves are products of the allosteric
effect of agonists on 7TMRs; this will be discussed fur-
ther in the section on functional selectivity (see section
V.C.2). However, for the purposes of discussing classic
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FIG. 6. Basic model for allosteric interaction of a modulator (A or B) interacting with a receptor (R) to affect the interaction of a guest (counterpart
A or B). If A is an agonist, then agonism can emanate from the species AR and/or the allosterically modified species ARB. The modulator would then
be B, which can affect the affinity of the agonist for the receptor (through ) or the efficacy of the receptor (relative efficacy of the species ARB/AR
described as ). This can result in a range of new responses to ligand A from potentiation to antagonism. The binding species are from the model given
by Ehlert (1988); the response components can be added through melding of that model with the operational model for receptor function (Black and
Leff, 1983) to yield a general functional model of allosteric 7TMR function (Ehlert, 2005; Kenakin, 2005; Price et al., 2005).
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guest allostery for cobinding ligands, agonists will be
considered as guest probes of receptor behavior that can
be modified by the modulating ligand. Therefore, a mod-
ulator can have varying effects (denoted as cooperativity
values) on the activity of probe molecules such as ago-
nists and radioligands. Two values that will be used to
describe modulatory effects on agonism will be , the
change in the affinity of receptor for an agonist observed
after modulator binding, and , the effect on agonist
efficacy. There are no constraints as to the vectorial
effect of each of these on a given 7TMR; i.e., a modulator
may increase affinity and reduce efficacy, increase both,
decrease both, or decrease affinity and increase efficacy.
These cooperativity values are described in terms of
their maximum value upon saturation of the allosteric
site. Thus, an  value of 10 denotes a 10-fold increase in
the affinity of the receptor for the probe upon complete
saturation of binding of the modulator to the allosteric
site.
Saturability of effect simply refers to the fact that,
whatever the allosteric effect, it will reach an asymptote
maximum when there is complete occupancy of the allo-
steric site. Competitive orthosteric ligands can produce
theoretically infinite competitive effects as long as the
concentrations of the competing ligands are manipu-
lated in the correct manner. Therefore, a competitive
antagonist can produce a dextral displacement of an
agonist concentration response curve that is limited only
by the experimental or viability constraints of the sys-
tem. In addition, if given in sufficiently high concentra-
tion, an orthosteric antagonist will render the receptor
protein completely unresponsive to guest effect through
mass action. In contrast, an allosteric modulator that
produces a 10-fold reduction in the affinity of a guest
ligand (  0.1) will produce up to a 10-fold shift in the
binding curve to that guest ligand and no more. Thus,
for low levels of allosteric modulation, the protein may
still be responsive to the guest ligand; i.e., effects can be
modulated, not obliterated. For example, 101.10 (Arg-
Tyr-Thr-Val-Glu-Leu-Ala), a peptide allosteric antago-
nist of IL-1 receptors produces a maximum 18-fold dex-
tral displacement of an 125I-IL-1 radioligand binding
curve, and no increase in the concentration of 101.10 will
reduce the affinity for 125I-IL-1 beyond that level
(Quiniou et al., 2008). These effects often are made man-
ifest as curves that show that the radioligand cannot be
completely displaced by the allosteric molecule (for exam-
ple, see Rominger et al., 2009). These patterns have on
occasion been incorrectly termed “partial” antagonism.
Because an allosterically modulated receptor has new
properties toward guest ligands, the affinity and efficacy
can be modulated in different ways; it is worth consid-
ering the possible effects than can lead to antagonism.
For example, allosteric antagonists may only reduce ag-
onist affinity and not affect agonist efficacy (in which
case it will resemble a limited effect competitive antag-
onist), or they can reduce both affinity and efficacy (to
produce either mixed competitive/noncompetitive ef-
fects). It is noteworthy that they also can reduce efficacy
without altering affinity. For example, the CCR5 allosteric
modulator aplaviroc minimally affects the binding of the
chemokine CCL5 to the receptor but completely blocks
CCL5-mediated agonism (Maeda et al., 2004; Watson et
al., 2005). Likewise, the noncompetitive metabotropic glu-
tamate receptor 1 antagonist 7-hydroxyiminocyclopropan-
[b]chromen-1a-carboxylic acid ethyl ester inhibits receptor
signaling without interfering with glutamate binding
(Litschig et al., 1999). An even more interesting effect is
seen with the NMDA receptor allosteric antagonist ifen-
prodil. This antagonist actually increases the affinity of the
agonist NMDA but blocks its efficacy (Kew et al., 1996).
Because allosteric effects are reciprocal, this means that
NMDA also increases the affinity of ifenprodil as a block-
ing agent. This adds the intriguing antagonist property of
increased potency in systems where agonist tone is high;
i.e., the blocker gets better the more the system is driven.
A similar effect is observed for the cannabinoid CB1 recep-
tor allosteric modulator 5-chloro-3-ethyl-1H-indole-2-carbox-
ylic acid [2-(4-piperidin-1-ylphenyl)ethyl]amide (Org27569)
(Price et al., 2005).
The previous discussion has been confined to classic
guest allostery whereby a modulator alters the interac-
tion of a guest molecule (usually binding from the extra-
cellular space) with the receptor. These effects can result
in a diminution of guest agonism (allosteric antagonism)
or potentiation of guest agonism (potentiation with mol-
ecules referred to as PAMs). The potentiation of agonist
effect can occur through an increase in endogenous ag-
onist affinity [i.e., brucine for acetylcholine agonists,
(Jakubík et al., 1997)] or efficacy [i.e., hexapeptide
growth hormone secretagogue for Ghrelin receptors,
Holst et al., 2009)].
Potentiation of endogenous response can only occur in
a permissive system (Kenakin, 2005) that allows cobind-
ing of the modulator and the endogenous agonist, so this
mechanism is accessible only through allosteric mole-
cules. One of the main unique features of positive allo-
steric modulators (PAMs) is the retention of complex
patterns of excitation. This occurs because the PAM
effect is proportional to the endogenous physiologic tone
already present in the system. In this way, geographical
patterns of innervation, such as those found in the CNS,
can be potentiated in correct proportion to the function
of the healthy system.
As discussed in the section(s) on functional selectivity
and biased agonists (section V.C.2), there is no simple
relationship between receptor binding of an agonist and
the activation of the spectrum of signaling pathways
that are mediated by that receptor; i.e., there is hetero-
geneity in the pathways activated by different agonists.
This is a result of the change in energy landscape pro-
duced by the binding of an allosteric modulator poten-
tially to cause a completely different array of behaviors
of the receptor toward binding of any guest ligand. This
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extends to PAMs as well in that the signaling pattern of
a given agonist acting on a receptor may change in the
presence of an allosteric antagonist (see section V.C.2.d)
or a PAM. For instance, allosteric potentiators of mGluR
receptors have been shown to differentially potentiate
mGluR5-mediated calcium transients and ERK1/2 phos-
phorylation (Zhang et al., 2005). In general, a number of
PAMs are currently being investigated for therapeutic
activity (see Bridges and Lindsley, 2008).
The other major effect of allosteric modulators ema-
nating from the property of permissiveness of binding of
coligands is probe dependence. Thus, the actual alloste-
ric effect that a given modulator has on a series of guest
molecules may be quite different for different guests
(Hejnova´ et al., 1995; Maass and Mohr, 1996; Jakubík et
al., 1997). For example, the CCR5 receptor modulator
aplaviroc blocks the binding of the chemokine CCL3 to
the receptor but not the binding of CCL5 (Watson et al.,
2005). This unique property can be exploited therapeu-
tically to enhance therapeutic potential, reduce second-
ary effects, and prosecute targets the natural function of
which cannot be compromised (see V.C.3).
Another feature of allosteric modulators is extraordi-
nary selectivity for receptor types (Melchiorre et al.,
1989; Ellis et al., 1991; Jakubík et al., 1995; Liang et al.,
1996; Gnagey et al., 1999; Johnson et al., 2004). This
may result from binding to sites on the protein that are
unique for a particular protein, as opposed to sites com-
mon to a set of proteins (i.e., binding site for common
neurotransmitter or hormone agonist, ATP substrate
binding, etc.). For example, although it is difficult to
demonstrate selectivity for kinases at ATP binding sites
(because they are common to all kinases), an allosteric
antagonist that binds to another site and modulates the
ATP site may be selective. Imatinib blocks the Bcr-abl
fusion protein with kinase activity in myelogenous leu-
kemia through an allosteric mechanism but does not
alter ATP interaction with the catalytic domain of other
kinases (Adria´n et al., 2006). Yet another advantage of
allosteric molecules is that they simply act on the phys-
iological tone that is already present; this preserves
complex patterns of activation (such as those due to
innervation networks in the brain) for better physiolog-
ical effect (Jakubík et al., 1997; Dolezal and Tucek, 1998;
Lazareno et al., 1998; Mo¨hler et al., 2002).
In keeping with the mechanism of creating new energy
landscapes for receptors, allosteric modulators basically
create new ensembles. The way these new ensembles in-
teract with different guests defines the pharmacology of
the modulator. This has ramifications for disease-re-
lated alterations in guest molecules. For example, HIV-1
infection is mediated by the interaction of the viral coat
protein gp120 with the CCR5 receptor, and the virus is
known to continually mutate and alter the composition
and conformation of gp120 in its routine realm of exis-
tence (Wyatt and Sodroski, 1998; Poignard et al., 2001).
The therapeutic relevance of this activity is that the
virus will probably learn to use whatever form various
HIV-1 entry inhibitors impose on the CCR5 receptor;
i.e., viral resistance is inevitable (Trkola et al., 2002;
Kuhmann et al., 2004). For an orthosteric mechanism,
the “blocked” CCR5 receptor would be identical for all
blockers; therefore, once viral resistance was attained,
all orthosteric CCR5 entry inhibitors would show resis-
tance. However, because allosteric ligands create new
ensembles, there is no rule a priori to suggest that the
various ensembles stabilized by different allosteric mol-
ecules will be identical; in fact, antibody binding evi-
dence suggests that the opposite is true. It has been
shown that the antibody binding profiles of Ab45531 and
Ab45523 differ for CCR5 in the presence of the allosteric
HIV-1 entry inhibitors TAK779, SCH-C, and aplaviroc
(Kenakin, 2007b), further suggesting that the conforma-
tions stabilized by these allosteric modulators differ
from each other. This suggests that different allosteric
modulators may produce different conformations that do
not resemble each other except for the fact that none of
them support HIV-1 entry. Under these circumstances,
it would be predicted that viral resistance to one alloste-
ric entry inhibitor could be overcome by use of another,
because a different conformation of the receptor (one
that the virus has not encountered) would be formed.
In summary, allosteric ligands, by virtue of the fact that
they provide a new energy landscape for the receptor, can
essentially create a new receptor. If the allosterically mod-
ified receptor prefers new global conformations, the inter-
action with large proteins (involving multiple binding
loci) may be altered. In addition, allosteric ligands have
unique properties in that they produce saturable and
probe-dependent effects; these can lead to correspond-
ingly special therapeutic properties. Finally, the adop-
tion of new conformations leads to potentially disso-
ciable effects on cobinding ligand efficacy and affinity,
and the combination of these two properties can also pro-
duce unique allosteric modulator behavior. It should be
stressed that there are no theoretical limitations on the
effects of an allosteric modulator on the function of other
ligands on the receptor; i.e., they may be antagonized
(NAMs), potentiated (PAMs), or unaffected.
2. Allosteric Agonists. Because allosteric modulation
can result in a globally different receptor, there also are
no limits to the potential direct effects a modulator can
have (Kenakin, 2007). Given this, the interaction of the
receptor with other guests can simultaneously be al-
tered. When this occurs for cytosolic guests that mediate
signaling, then a direct agonist effect of the modulator
on cell function may be observed. Allosteric agonists
produce direct activation of receptors through binding at
a site other than the binding site for endogenous ago-
nists. PAMs often can be shown to produce direct ago-
nism in highly sensitive systems, a finding that perhaps
should not be surprising, because PAMs stabilize ago-
nist-activated conformations of receptors to produce po-
tentiation of effect (Schwartz and Holst, 2007). Alloste-
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ric agonists may pose unique problems in validations
because the resulting allosteric agonism may not be
sensitive to conventional orthosteric antagonists. For
example, the muscarinic receptor agonism produced by
alcuronium is insensitive to the blocking effects of the
orthosteric antagonist quinuclidinyl benzilate (Jakubík
et al., 1996). Likewise, the effects of the peptide agonists
for CXCR4 receptors RSVM and ASLW are insensitive
to the antagonist AMD3100 (Sachpatzidis et al., 2003).
In addition, as discussed in terms of allosteric modula-
tors in general, allosteric agonists have the potential for
great selectivity because they target unique loci on re-
ceptor subtype proteins (Jones et al., 2008). Allosteric
agonists also have been shown to be functionally selec-
tive and bias their signaling toward different pathways
mediated by the receptor (Thomas et al., 2008); these
ideas will be developed more fully in the following sec-
tions on functional selectivity and agonist bias (section
V.C.2.c). Similar to positive signaling effect through al-
losteric modulation, allosteric antagonists (NAMs) also
have the potential to induce a negative direct effect on
the receptor (allosteric inverse agonism). In this case,
the direct allosterically stabilized conformation of the
receptor would not interact with signaling proteins to
produce visible positive response. In addition, as with
orthosteric inverse agonists, an allosteric inverse ago-
nist would reverse constitutive activity to produce in-
verse agonism in constitutively active receptor systems.
Finally, a new unique class of ligand has emerged, spe-
cifically for muscarinic receptors. Termed “bitopic,”
these molecules interact with both the orthosteric and
allosteric site on the receptor to self-modulate their own
activity (Valant et al., 2008, 2009).
3. Seven Transmembrane Receptor Allostery and New
Drug Discovery. In the quest for new allosteric ligands,
the fact that the species of interest is a ternary complex
of modulator/conduit/guest has ramifications for the
screening of modulators. A new mode of screening must
be adopted in which new molecules are tested in assays
containing a low level of cobinding ligand already
present. The resulting data describes ligands in terms of
the concentration at which an effect is observed versus
the effect on the response (or binding) of the reference
ligand. Therefore, two parameters are needed to fully
describe an allosteric modulator: the affinity of the mod-
ulator for the 7TMR and the cooperativity observed with
the coligand (i.e., a value for change in affinity or po-
tency, etc). In this sense, reporting data for modulators
is the same as for agonists in which a potency (EC50) and
maximal response is needed to describe the profile of
activity. For a modulator, an added complication is the
fact that the identity of the cobinding ligand is also
relevant because probe dependence can make modulator
effects differ for different guest molecules. In this re-
gard, probe dependence requires that, wherever possi-
ble, the natural endogenous ligand interacting with the
receptor be present in the screening milieu to detect
physiologically relevant interactions. For example, when
screening for cholinergic PAMs for use in Alzheimer’s
disease, it would be chemically preferable to use a stable
cholinergic ligand in the place of acetylcholine, an un-
stable molecule that is difficult to control under screen-
ing conditions. However, many PAMs potentiate surro-
gate ligands (such as arecoline and carbachol) but
actually inhibit acetylcholine (Jakubík et al., 1997) and
thus are not therapeutically useful. This type of probe
dependence could lead screening efforts astray in that
nonphysiologically relevant potentiators of agonism
would be discovered.
Another possible consideration is kinetics, because
many allosteric modulators have an unusually long re-
quirement for attainment of kinetic equilibrium (long
times of onset on and offset off of the receptor). For
example, the allosteric CCR5 modulator aplaviroc has a
requirement of 2 to 3 h for onset and has a t1/2 for
dissociation on the order of hundreds of hours (Watson
et al., 2005). Likewise, persistent kinetics have been
reported for muscarinic allosteric modulators (Jakubík
et al., 2002; Machova´ et al., 2007) and p38 kinase inhib-
itors (Pargellis et al., 2002). In keeping with the notion
that an allosteric site may be distant from the endoge-
nous agonist binding site and may in fact be part of a
relatively rare ensemble present only for a fraction of
the lifetime of energy landscape, it has been proposed
that this is the reason some allosteric modulators are
slow to bind to the protein. In practical terms, this
suggests that exceedingly long incubation times may be
required to detect weak allosteric modulators in a
screening environment.
To fully characterize an allosteric effect, the modula-
tor/conduit/guest ensemble must be specified and the
effects of the modulator on the guest characterized
quantitatively. This can be done by comparing data with
output from quantitative models (Ehlert, 2005; Kenakin,
2005; Price et al., 2005), where the effect on affinity ()
and efficacy () can be calculated. For functional studies,
a powerful tool that also can be used is the measurement
of allosteric modulation of agonist effect through calcu-
lation of changes in agonist “activity ratios” (the ratio of
the maximal response to the agonist and the EC50 molar
concentration that produces half-maximal response)
(Ehlert, 2005).
In summary, drug discovery for allosteric modulators
requires certain special considerations such as the need
to quantify both potency and cooperativity, the acknowl-
edgment of probe dependence (the natural agonist must
be used), and the accommodation of possibly slow kinet-
ics. A simple combination of the Ehlert (1988) and Black/
Leff (Black and Leff, 1983) models for allosterism and
operational agonism, respectively, can be used to assign
quantitative parameters to allosteric modulators.
4. Therapeutic Application of Allosteric Modulators. In
light of the ability of PAMs to preserve complex patterns
of agonism, central nervous system targets in which the
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endogenous system is failing are obvious areas where
these molecules can be used therapeutically in diseases
such as Alzheimer’s disease and in other cases of failing
cholinergic innervation (Bartus et al., 1982). One clinical
approach has been to potentiate cholinergic effect through
cholinesterase inhibition (Flicker, 1999), but this strategy
seems to have limited practical value (Nordberg and
Svensson, 1998; Rogers et al., 1998; Maelicke et al., 2000).
Coupled with the obvious potential liability to be encoun-
tered with cholinesterase inhibition, it may be that cho-
linesterase inhibitors produce relatively nonselective in-
creases in cholinergic function through both nicotinic and
muscarinic receptors (Fisher, 1999; Maelicke et al., 2000),
whereas selective potentiation of nicotinic responses is re-
quired (Rogers et al., 1998). Under these circumstances, a
preferable approach would be to selectively potentiate nic-
otinic receptor function through PAMs (Maelicke and Al-
buquerque, 1996; Krause et al., 1998). Likewise, potentia-
tion of the effects of adenosine has been proposed to be
beneficial in localized areas of oxygen deficit such as an-
gina, myocardial infarction, and stroke (Fredholm, 2007;
Romagnoli et al., 2008). In addition to cardiovascular dis-
ease, PAMs have also been postulated to be of value in the
treatment of psychoses and cognitive disorders via poten-
tiation of mGluR5-mediated responses (O’Brien et al.,
2003). With regard to schizophrenia, it has been proposed
that positive modulation of mGluR2 and mGluR3 recep-
tors could be beneficial in treating positive symptoms,
whereas positivemodulation of mGluR5 could be useful for
treating all major symptoms [positive, negative and cogni-
tive (Conn et al., 2009b)]. Likewise, selective potentiation
of muscarinic m4 receptor responses to regulate brain lev-
els in psychosis with the PAM 3-amino-5-chloro-6-me-
thoxy-4-methyl-thieno[2,3-b]pyridine-2-carboxylic acid cy-
clopropylamide (LY2033298) has been proposed as a novel
antipsychotic drug (Chan et al., 2008). A comprehensive
description of the application of allosteric molecules to a
range of psychiatric disorders is given in Conn et al.
(2009a).
In terms of receptor antagonism, allosteric modula-
tion has certain distinct advantages, especially in terms
of probe dependence, where there is the possibility of
blocking some interactants for a receptor but not others.
For example, blockade of the CCR5 receptor is a mech-
anism to prevent HIV-1 infection. However, high levels
of chemokines have been associated with delay of AIDS
progression (Lori et al., 1997; Ullum et al., 1998; Gar-
zino-Demo et al., 1999; Shieh et al., 2001; Heredia et al.,
2003; Rogez et al., 2003; Xiang et al., 2004), suggesting
it may be advantageous to preserve CCR5-chemokine
interaction in AIDS. In fact, a study of 1064 patients
infected with HIV in 57 populations around the world
showed a strong inverse correlation between the gene
copy number for the chemokine CCL3L1 (this is variable
in humans) and progression to AIDS. Specifically, pa-
tients with high CCL3L1 gene copy number showed a
highly statistically significantly greater survival rate
compared with patients with low CCL3L1 copy number
(Gonzalez et al., 2005) . The mechanism for this effect is
thought to be removal of CCR5 cell receptors through
internalization into the cytosol (Alkhatib et al., 1997;
Amara et al., 1997; Mack et al., 1998), and an inverse
link between CCL3L1 and CCR5 receptor levels has
been reported (Ketas et al., 2007). Therefore, a function-
ally selective CCR5 modulator that blocked the binding
of HIV-1 gp120 protein but otherwise preserved CCL3L1
function through the receptor (to enable the chemokine
to internalize the receptor) would theoretically offer a
more efficacious profile (Muniz-Medina et al., 2009).
B. Lateral Allostery (Dimerization, Complexation)
1. Receptor Oligomerization and Structure. The con-
cept of 7TMRs associating with each other within the
plane of the plasma membrane has been the focus of
extensive debate (Bouvier, 2001; Angers et al., 2002;
James et al., 2006; Milligan et al., 2006). Having seven
transmembrane segments gives these molecules every
opportunity for nonspecific hydrophobic interaction and
aggregation with other membrane proteins. Anyone who
works with these molecules in the laboratory has had
the chance to see this behavior firsthand. It is because of
this behavior that many groups have been skeptical
about 7TMR oligomerization. There are now a series of
experimental manipulations, including saturation ex-
periments and use of very low levels of expression in
recombinant systems that are analogous to those that
exist in nature, that are required as part of the evalua-
tion of true, biologically relevant 7TMR oligomerization.
Even with these manipulations yielding positive results,
skeptics remain. However, there are compelling data to
support the existence of structurally specific oligomer-
ization of some 7TMRs, many of these interactions hav-
ing substantial functional implications.
Although the interactions between single transmem-
brane tyrosine kinase receptors have long been recog-
nized as providing the fundamental mechanism for their
cross-phosphorylation, no such clear function has been
identified for 7TMR association. Nevertheless, there are
examples of 7TMR association (oligomerization) affect-
ing the affinity and specificity of ligand binding, the
pattern of signaling, and internalization. For 7TMRs in
family A, the full spectrum of observations have been
recorded, from having no effect on function to each of the
described functional changes, and from ligand binding
leading to dissociation of the oligomeric complex to hav-
ing no effect. There are clearly no rules yet for which
subset of such receptors oligomerizes or which has a
particular functional effect.
It is interesting that family C 7TMRs have a very
compelling structural and functional story for their as-
sociation. Many family C 7TMRs seem to require asso-
ciation as dimers, some of these even acquiring covalent
stabilization with disulfide bonds. There are beautiful
crystal structures of dimeric complexes of amino-termi-
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nal domains of family C 7TMRs, with a single natural
ligand spanning the protomers (de Vos et al., 1992).
Homodimeric calcium-sensing receptors and metabotropic
glutamate receptors can have disulfide bonds linking their
Venus flytrap domains, as well as possessing a number of
other noncovalent stabilizing interactions.
Family B 7TMRs have also recently been shown to
associate as stable homo-dimers. The structural basis of
this, at least for the prototypic secretin receptor, is the
lipid-exposed face of TM4 (Harikumar et al., 2007; Hari-
kumar et al., 2008; Gao et al., 2009). This complex has
been postulated as being important for the structural
stabilization of the high affinity complex with G protein.
It will be interesting to determine whether this pattern
is reproduced for other members of family B.
a. Interactions of seven transmembrane receptors with
other membrane proteins. The most dramatic and in-
teresting association with 7TMRs was identified in an
attempt to clone the receptor for calcitonin gene-related
peptide. In that effort, using expression cloning, a single
transmembrane protein was identified that ultimately
was named RAMP (Foord and Marshall, 1999). Subse-
quently, two homologous RAMPs were cloned (RAMP1,
RAMP2, and RAMP3). The story for RAMP association
with 7TMRs and how they can modify the function of
those receptors is indeed fascinating (Hay et al., 2006).
RAMP1/calcitonin-like receptor behaves phenotypi-
cally as a calcitonin gene-related peptide receptor,
whereas RAMP2 and RAMP3 association with the cal-
citonin-like receptor exhibits adrenomedullin pheno-
types. RAMP association with the calcitonin receptor
assumes an amylin receptor phenotype. Other family B
7TMRs have also been shown to associate with RAMPs
and to elicit no particular pharmacological profile. These
include parathyroid hormone (PTH) 1, PTH2, VPAC1,
and glucagon receptors; the VPAC1 receptor is able to
associate with all three RAMPs, PTH1, and glucagon
receptors able to associate with only RAMP2, and the
PTH2 receptor is able to associate only with RAMP3. In
contrast, other family B 7TMRs, including VPAC2,
growth hormone-releasing hormone, GLP-1, and GLP-2
receptors seem to not associate with RAMPs. The struc-
tural basis for RAMP association with these receptors
has been postulated to be affected by amino-terminal
regions and by transmembrane segments, but no clear
theme has yet emerged.
It is likely that other transmembrane proteins will
also follow this theme and associate with 7TMRs within
the lipid bilayer. It is not yet clear what such interac-
tions might exist, their stability, or their functional im-
portance. Such interactions could well be contributing to
some of the observed differences in function and regula-
tion of specific receptors expressed in different natural
cellular environments, or even in the differences in re-
ceptor function and regulation in pathological environ-
ments, such as in tumor cells.
b. Influence of the lipid microenvironment. Lipids
are known to play important roles in 7TMR signaling
(Escriba´ et al., 2007; Paila and Chattopadhyay, 2009).
Many 7TMRs are themselves reversibly palmitoylated,
typically within their carboxyl-terminal tail, where this
modification helps to form a fourth intracellular loop
region that has been shown to have regulatory proper-
ties. In addition, fatty acid acylation of G subunits and
isoprenylation of G subunits helps to direct these to the
plasma membrane for their interaction with the recep-
tors. Recent crystal structures of rhodopsin have also
clearly demonstrated preferential sites of interaction
with cholesterol. Many observations over the years have
suggested that the lipid microenvironment of some par-
ticularly sensitive 7TMRs could affect their function,
typically by affecting G protein coupling. Although the
lipid-exposed faces of the 7TMR helical bundles can have
allosteric effects on these membrane proteins, this may
be difficult to take advantage of in a direct way by
interacting drugs. It is hard to achieve specificity of
interaction in the absence of a specific pocket to target.
However, indirect effects on sensitive receptors may well
be possible.
2. Receptor Oligomerization and Function. There is
considerable evidence to indicate that 7TMRs can form
and function as homodimers and heterodimers (Milligan
and Smith, 2007; Gurevich and Gurevich, 2008; Milli-
gan, 2008; for reviews, see Franco et al., 2008a) and that
these dimers may have therapeutic relevance (Bouvier,
2001; Breitwieser, 2004; Franco et al., 2005, 2008b).
There also are mathematical models to detect, charac-
terize, and quantify receptor dimerization on the level of
binding (Durroux, 2005; Albizu et al., 2006; Franco et
al., 2006; Casado´ et al., 2007; Giraldo, 2008) and func-
tion (Franco et al., 2006). Association of receptors within
cell membranes constitutes the lateral transduction of
information through allosterism; it is worth considering
some types of interactions that have been reported.
There are several ways to examine lateral allosterism
with ligands and proteins changing roles of modulator,
conduit, and guest. Among the most commonly reported
data are studies of ligands interacting with each other
through a receptor dimer. Phenotypes observed for re-
ceptor dimers are mediated by laterally induced alloste-
ric effects that change the conformation(s) of the recep-
tors involved. In fact, such effects have directly been
observed in a leukotriene B4 dimer through a fluores-
cently labeled 5-hydroxy-tryptophan labeled protomer
(Damian et al., 2006). This can lead to production of a
unique therapeutic effect because the activity of ligands
is conferred by systems only producing receptor dimers.
In these types of systems, the conduit is the dimeric
receptor complex with the ligands taking on the role of
modulator and guest; see Fig. 7A. The pharmacologic
effect is transferred through one receptor and made
manifest in the dimeric receptor complex, an effect re-
ferred to as “off-target” allosterism (Ballesteros and
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Ransom, 2006). These effects can be seen on the level of
receptor binding. For example, heterodimerization of so-
matostatin SSTR5 and the dopamine D2 receptors al-
lows crossed activity of dopamine and somatostatin li-
gands. Specifically, the potency of the somatostatin
ligand SST-14 (in competition binding with the radioli-
gand 125I-Leu8-D-Trp22-Tyr25-SST-28) is increased 30-
fold by the dopamine agonist quinpirole and reduced
80% by the dopamine antagonist sulpiride in cells con-
taining SSTR5/D2 heterodimers (Fig. 7A) (Rocheville et
al., 2000). Likewise, heterodimerization of CCR2b and
CCR5 receptors causes the CCR5 receptor, normally
insensitive to MCP-1 (monocyte chemoattractant pro-
tein-1) binding, to bind MCP-1; likewise, the CCR2b
receptor, normally insensitive to the CCR5 chemokine
ligand CCL4 binds CCL4 when dimerized with CCR5
(El-Asmar et al., 2005). Studies with a dopamine D1-
dopamine/D3-dopamine receptor heterodimer (D1-D3
dimer) show that binding of agonists to the D3 protomer
of the dimer complex increases the affinity of the D1
receptor for agonists within the dimer (Marcellino et al.,
2008). Other examples include the reduction in the af-
finity of adenosine A1 protomers for agonists upon bind-
ing of adenosine A2A receptor agonists to A2A receptors
in an A1-A2A receptor heterodimer (Ciruela et al., 2006)
and reduction in the affinity of dopamine D2 receptors
for dopamine through stimulation of adenosine A2A re-
ceptors in a A2A-D2 heterodimer (Ferre et al., 1991).
These effects can be seen in functional studies as well.
Thus, the agonist effects of orexin-A can be reversed
by the cannabinoid receptor CB1 inverse agonist SR141716A
through formation of an orexin-1/CB1 receptor het-
erodimer (Hilairet et al., 2003). Conformational changes
in dimers open the possibility of changes in receptor-
mediated signaling in cells. Under these circumstances,
the receptor dimer is considered a single species (Levoye
et al., 2006) to affect guest cytosolic signaling proteins.
Changes in receptor sensitivity to agonists upon dimer-
ization have been well characterized, notably for opioid
receptor heterodimers. For instance, reduced potency
and changes in the agonist rank order of potencies to
synthetic opioid agonists for - and -opioid receptors
have been shown in systems in which - and -opioid
receptors are coexpressed. In contrast to the reduced
synthetic ligand potencies, enhanced affinities for the
peptide agonists endomorphin-1 and Leu-enkephalin
were seen in these systems (George et al., 2000). Strik-
ing alterations have been observed with dimerization
involving actual changes in the nature of receptor sig-
nals upon receptor dimerization (Ferre´ et al., 2007).
Thus, dopamine D2 receptors, normally coupled to Gi-o
proteins as monomers, switch their coupling to Gq/11
proteins upon dimerization with dopamine D1 receptors
when theD1 receptor is coactivatedwith agonist (Rashid et
al., 2007). In addition, although the ligand 6-chloro-2,3,4,5-
tetrahydro-3-methyl-1-(3-methylphenyl)-1H-3-benzaz-
epine-7,8-diol (SKF83959) does not activate adenylate cy-
clase or Gq through either D1 or D2 dopamine receptor
monomers, it does activate Gq/11 via the D1-D2 heterodimer
(Rashid et al., 2007). Likewise, the potency of orexin-A,
in producing phosphorylation of ERK1/2 is increased
100-fold upon heterodimerization of the orexin-1 recep-
tor with cannabinoid CB1 receptors, but the effect is
pathway-dependent. Specifically, no increased potency
for orexin-A inositol phosphate production is observed
upon heterodimerization (Hilairet et al., 2003).
In addition to receptors, allosteric information can be
transducer laterally to other membrane proteins such as
RAMPs to yield unique functional receptor phenotypes
(Hay et al., 2004, 2006; Udawela et al., 2006). For ex-
ample, human calcitonin is 20-fold more potent than rat
amylin in melanophores transfected to express human
calcitonin receptors (Gq protein activation); this relative
potency is reversed by the cotransfection of RAMP3
(amylin becomes 3-fold more potent than human calci-
tonin) (Armour et al., 1999). Thus human calcitonin and
rat amylin become modulators for the conduit human
calcitonin receptor-RAMP complex with Gq protein as
the guest. It can be seen that other receptors or mem-
brane proteins cobinding to the receptor can confer func-
tional selectivity upon systems in a manner similar to
external allosteric modulators.
Although it is customary to consider small molecules
or peptides as allosteric modulators, it should be noted
that large cytosolic proteins can be considered allosteric
modulators as well. Although this has been well estab-
lished in the case of G proteins (Kostenis, 2006; Kostenis
et al., 2005), it also is true of membrane-bound proteins.
Under these circumstances, the receptor is the conduit
protein acted on by a second dimerizing receptor, which
becomes the allosteric modulator sensed by guest li-
gands (Fig. 7B). Thus, the efficacy of angiotensin I in
HEK293 cells increases upon heterodimerization of the
angiotensin receptor with bradykinin-2 receptors (Fig.
A  Receptor Dimer as Conduit B  Receptor Protomer as Modulator
Receptor Oligomerization
Conduit
Modulator
Modulator
Guest
Conduit
Guest
FIG. 7. Two types of allosteric system derived from receptor oligomers.
A, the receptor dimer becomes a completely new conduit and ligands
interact through this new conduit with revised interactive behaviors. For
example, the dopamine antagonists quinpirole and sulpiride bind to a
somatostatin SSTR5-dopamine receptor D2 heterodimer to block the
binding of somatostatin (Rocheville et al., 2000). B, another receptor (or
membrane bound protein such as RAMP) becomes the modulator that
confers new reactivity toward a guest through a receptor. For example,
the bradykinin-2 receptor can act as a modulator and bind to the angio-
tensin1 receptor to change the binding characteristics of angiotensin-1
(AbdAlla et al., 2000).
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6B) (AbdAlla et al., 2000). These types of effects can be
seen with antagonists as well. Thus, the affinity of caf-
feine for the adenosine A2A receptor falls by a factor of 10
when the receptor heterodimerizes with the adenosine
A1 receptor (Ciruela et al., 2006). The cannabinoid CB1
receptor becomes a modulator of the orexin-1 receptor,
causing it to be actively internalized (in this case, the
guest is the cytosolic component that interacts with the
receptor during internalization, presumably -arrestin)
(Ellis et al., 2006). In addition to receptors acting as
active modulators, other membrane proteins can fill this
role as well. For example, RAMP3 actively modulates
human calcitonin receptors to cause a 7-fold reduction in
the affinity of the amylin antagonist AC66 (salmon cal-
citonin [8–32], pKB for blockade of amylin response 9.7
without RAMP3; coexpression of RAMP3, pKB  8.85)
(Armour et al., 1999).
In summary, there are two general mechanisms by
which lateral allosterism can affect drug effect with
dimerization. In one, the dimerizing protein (other re-
ceptor, RAMP) binds to the receptor to form a new con-
duit with allosterically altered characteristics toward
both modulators and guest (Fig. 7A). The other involves
the cobinding protomer (other receptor, RAMP) as the
modulator in a multisite allosteric system in which the
protomer alters the signaling effects of the agonist-
bound receptor as it interacts with cytosolic molecules
(Fig. 7B). This is an increasingly described phenomenon
in the literature with possible therapeutic application in
new drug discovery.
3. Therapeutic Application(s) of Receptor Oligomers. For
some receptors (i.e., tyrosine-kinase receptors), dimer-
ization is a known mechanism of action (Heldin, 1995).
The increasing importance of dimerization for 7TMRs
naturally suggests its possible relevance to drug discov-
ery (George et al., 2002). Thus, if new drug-sensitive
phenotypes for existing receptors are formed upon
dimerization, then selective drug effect could result.
There are provocative links between therapeutic profiles
of some drugs and dimers. For example, functional se-
lectivity in antagonism for typical and atypical antipsy-
chotic interaction with 5-HT2A receptors has been linked
with receptor dimerization (Brea et al., 2009). Oligomer-
ization seems to be especially prevalent among opioid
receptors; this has been shown to yield many opioid
receptor phenotypes in tissues (defined as 1, 2, 1, 2,
1, 2, 3). In terms of acquisition of new drug sensitiv-
ity through oligomerization, the agonist 6-guanidinoal-
trindole (6-GNTI) produces no agonist response at
-opioid receptors and very little at -opioid receptors.
However, this agonist produces powerful responses on
the heterodimer of - and -opioid receptors (Waldhoer
et al., 2005). These responses to 6-GNTI are blocked by
antagonists of both - or -opioid receptors. Of possible
therapeutic relevance is the fact that 6-GNTI produces
analgesia only when administered into the spinal cord,
suggesting that the dimerization is organ-specific. This
could lead to reduction in side effects with spinal anal-
gesia as a projected drug phenotype. Likewise, com-
plexes of glutamate receptors mGluR2 and serotonin
receptor type 5-HT2A have been specifically associated
with hallucinogenic responses in schizophrenia (Gonza´-
lez-Maeso et al., 2008).
An intuitively obvious advantage of targeting receptor
dimers therapeutically is the possibility of reducing
global activity to one of tissue-specific relevance. How-
ever, an opposite effect may be useful as well. Chemo-
kine signaling is known to be particularly pleiotropic
with chemokines showing cross-reactivity to a number of
chemokine receptor types (Mantovani, 1999; Wells et al.,
2006). In cases in which more than one chemokine re-
ceptor is targeted in inflammatory disease, the produc-
tion of receptor dimers can confer sensitivity of multiple
receptor types for a single antagonist. Such effects have
been noted for CCR2/CXCR4 receptor heterodimers
(Sohy et al., 2007).
C. Cytosolic Allostery: Functional Selectivity and
Biased Ligands
1. Functional Selectivity and Structure.
a. Interactions with G proteins. Despite the evolved
diversity in themes for natural ligand binding and even
differences in the structures of the helical bundle re-
gions, all the members of this superfamily associate with
a small number of heterotrimeric G proteins (Bourne,
2006; Johnston and Siderovski, 2007; Oldham and
Hamm, 2008). As noted above, only in family A 7TMRs
do we have a clear picture of the types of molecular
motion associated with the exposure of the G protein-
binding region upon agonist binding. This region is ex-
posed on the cytosolic surface of the helical bundle and
tends to have contributions from the bottom of key he-
lical segments, particularly TM6. Residues within each
of the cytosolic loop regions and the proximal carboxyl-
terminal tail region have been reported to influence G
protein coupling, based largely on loss-of-function site-
directed mutagenesis studies. It is particularly interest-
ing that mutations in these regions have been reported
to differentially affect coupling with one particular G
protein, with coupling to other G proteins being undis-
turbed (Wu et al., 1999). Therefore, although there may
be overlap in the coupling interface for different G pro-
teins (something we would expect, based on the large
relative size of the heterotrimeric G protein complex),
the details of the interactions with each specific G pro-
tein are distinct and can be differentially modified. An
extension of this is the prediction that different drugs
might stabilize the coupling with distinct G proteins in a
differential manner. Indeed, such observations have al-
ready been made. Our understanding of the molecular
basis of G protein coupling has recently improved sub-
stantially, based on the crystal structure of opsin cou-
pled with the peptide representing the carboxyl termi-
nus of transducin (Scheerer et al., 2008).
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The assumption is that family B and family C 7TMRs
couple to G proteins in a similar manner, but there are
minimal data to support this at the current time. Site-
directed mutagenesis of residues in similar cytosolic face
regions of these receptors has also produced loss-of-func-
tion phenotypes, but the details of the molecular basis
for exposure of these regions for G protein association is
currently unclear (Chan et al., 2001; Tams et al., 2001).
b. Interactions of seven transmembrane receptors with
other cytosolic proteins. Arrestin represented one of the
first proteins, other than heterotrimeric G proteins,
shown to directly interact with 7TMRs. Visual arrestin
was shown to bind to phosphorylated rhodopsin in 1985
(Ku¨hn et al., 1984; Pfister et al., 1985). Later, it became
clear that there was a family of arrestins, with a second
visual arrestin identified in cones and with two nonvi-
sual arrestins identified (arrestins 2 and 3, or -arrestin
1 and 2) (Prossnitz and Sklar, 2006; Gurevich et al.,
2008). There has been a consistent theme of these cyto-
solic proteins interacting with phosphorylated regions of
7TMRs, particularly those representing the sites of ac-
tion of G protein-coupled receptor kinase action. It is
also noteworthy that nonphosphorylated intracellular
loop and tail regions of 7TMRs have also been shown to
contribute to association with arrestins. This binding
has been described as sequential and multisite, with
both activation sensor that seems to bind to receptor
determinants that are exposed upon conformational
change (activation) and a phosphate sensor that binds to
the sites of receptor phosphorylation. Having these two
binding determinants provides the possibility of modify-
ing affinity of binding, further conformational changes
in the arrestin that can expose sites for binding of other
associated proteins, and that can regulate release and
recycling of the arrestin in the regulatory cycle.
7TMR-arrestin association has typically been de-
scribed as contributing to receptor desensitization via
uncoupling the receptor from its heterotrimeric G pro-
tein and via internalization by moving the receptor off
the cell surface where ligands would interact with it.
The latter seems to be mediated by the direct binding of
arrestins 2 and 3 to clathrin, a major structural element
of the endocytic machinery. Arrestin also associates with
other proteins involved in trafficking and endocytosis,
including phosphoinositides, activator protein 2, N-eth-
ylmaleimide-sensitive factor, ADP-ribosylation factor 6,
and ADP-ribosylation factor nucleotide-binding-site opener
(i.e., ARNO) (Shenoy and Lefkowitz, 2005; DeWire et al.,
2007). Arrestins also act as more general scaffolds, bind-
ing several MAPK family members and nonreceptor ty-
rosine kinases that may be critical for many intracellu-
lar signaling events. They also can direct endocytosed
proteins for ubiquitination, by associating with E3 ubiq-
uitin ligase Mdm2. The structural basis for the interac-
tion of arrestin molecules with both 7TMRs and other
signaling and regulatory molecules has been thoroughly
explored, with distinct determinants for many of these
processes (Gurevich and Gurevich, 2006). These can
even be dissociated by means of use of various arrestin
mutants. It is particularly interesting that receptor-ar-
restin signalsomes do not require heterotrimeric G pro-
teins for their signaling. Indeed, this is the molecular
basis first identified as mediating biased agonism at
7TMRs.
Another group of important 7TMR-interacting pro-
teins are PDZ domain proteins (Bockaert et al., 2004).
Many 7TMRs express an endogenous PDZ ligand at
their distal carboxyl termini (Bockaert et al., 2003). This
typically involves the terminal three or four residues,
representing the minimal sequence that binds to PDZ
domains. Three classes of PDZ ligands have been de-
scribed: class I (-E-S/T-xV/I), class II (--x--), and class
III (--x--), in which  represents an acidic residue and
 represents a hydrophobic residue (Sheng and Sala,
2001). The most studied PDZ-containing partner of
7TMRs is the Na/H exchange regulator factor 1.
Many other similar partners have been described previ-
ously (C kinase 1 protein, Golgi reassembly stacking
protein, glutamate receptor interacting protein, and
nebulin molecules). A PDZ domain typically consists of
80 to 100 residues forming six -strands and two -he-
lices. The carboxyl-terminal tail of the 7TMR is believed
to interact with an elongated surface groove that is
situated between the second -strand and the second
-helix in an antiparallel manner. The functional impli-
cations of such interactions are as diverse as the PDZ
domain-containing proteins. Functions related to intra-
cellular trafficking, transcriptional regulation, and cell
growth have been postulated.
2. Operational Mechanisms of Functional Selectivity.
a. Historical perspective. Perhaps the most impor-
tant single concept in pharmacology is that of the recep-
tor and its role as the primary recognition unit for neu-
rotransmitters and hormones (Rang, 2006). This idea
put order in otherwise diverse physiological responses to
chemicals; by implication, the receptor was thought to be
the minimal unit of interaction transmitting chemical
signals to cells. The necessary corollary to this idea is
that the relative potency of activators (agonists) of this
minimal unit should be constant if measured in the
same tissue under the same conditions. This is because
the relative potency of agonists would then be a complex
function of parameters unique only to the chemical
structures of the agonists, namely affinity and efficacy.
This idea formed the basis of receptor classification be-
fore biochemical characterization of receptors was pos-
sible, and it was enormously valuable in the classifica-
tion of receptor types and subtypes.
Over the past 20 years, instances in which the relative
activity of agonists did not adhere to the predictions of
simple receptor theory were noted with some agonists
for some receptors. (Roth and Chuang, 1987; Mottola et
al., 1991; Roerig et al., 1992 Fisher et al., 1993; Gurwitz
et al., 1994; Lawler et al., 1994; Ward et al., 1995;
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Heldman et al., 1996; Mailman et al., 1998; Lawler et
al., 1999). To consider these data further, it is important
to note the reliance of the predictions of constant agonist
potency ratios on the definition of efficacy. Until the
1980s, the scale for efficacy was system response either
in the form of a complex whole-tissue response (e.g.,
contraction, secretion) or defined single biochemical
measure (e.g., cyclic AMP). Although it was known that
7TM receptors are pleiotropic with respect to the num-
ber of cytosolic elements with which they can interact
(e.g., multiple G proteins) (Offermanns et al., 1994;
Prather et al., 1994, 2000; Gudermann et al., 1996; Wise
et al., 1999; Burford et al., 2000; Albert and Robillard,
2002; reviewed in Hermans, 2003), measures of response
and efficacy at that time were single amalgamated mea-
sures of cell activation. Early formulations of receptor
activation of 7TM receptors considered the receptors
mainly as rheostats controlling a single uniform signal
varying only in intensity. In terms of this concept, differ-
ential signaling could still occur but only in terms of a
strength-of-signal scale; i.e., the most sensitive signal
would be activated first followed by less efficiently coupled
processes. Such effects could be mediated by agonist effi-
cacy and/or the receptor density on the cell membrane. For
example, the opioid receptor agonist [D-Ala2-D-
Leu5]enkephalin inhibits basal cyclic AMP in NG 108-
115 cells (Costa et al., 1988) and also stimulates high-
affinity GTPase. Reduction of the receptor density
through alkylation produces a preparation less sensitive
to opioid receptor stimulation; under these conditions,
the less sensitive response (GTPase stimulation) is elim-
inated and only the most sensitive response (inhibition
of adenylate cyclase) remains. A similar effect has been
observed for muscarinic receptor contraction of guinea
pig ileum. In this case, oxotremorine is 2-fold more po-
tent than carbachol as an agonist. However, upon reduc-
tion of the receptor density through alkylation with phe-
noxybenzamine, the responses to oxotremorine are
completely eliminated, whereas the response to carba-
chol is diminished but still present. The reason for this
disparity in agonism is the fact that oxotremorine is a
high-affinity but low-efficacy agonist (more sensitive to
decreases in receptor number) and carbachol is a low-
affinity but high-efficacy agonist (more resistant to dim-
inution of tissue sensitivity). These data indicate how
the strength of a pharmacological signal can appear as
functional selectivity. However, this mechanism yields
data that does not require the postulate of separate
agonist-induced receptor active states (Kenakin, 1995a).
Such strength-of-signal effects produce cell-based func-
tional selectivity that is not associated with selective
stabilization of receptor conformation by agonists
(Kenakin, 2007c). The fact that this effect is cell-
dependent makes it difficult to harness under clinical
conditions and thus of limited therapeutic interest and
relevance. A typical pattern of functional selectivity
based on stimulus strength would show a low- and high-
efficacy agonist both capable of producing activation of
one signaling pathway and the agonist of higher efficacy
showing activation of the second pathway, whereas the
lower efficacy does not.
Once multiple measures of efficacy could be deter-
mined from a single receptor it became clear that the
idea of the receptor itself being the minimal trafficking
unit for chemical information to the cell was obsolete.
One of the earliest and most striking examples of lack of
adherence to the idea that the receptor is the minimal
unit of signal transduction for the cell was found with
PACAP. In LLC-PK1 cells transfected with PACAP re-
ceptor, the relative potencies of the PACAP analogs
PACAP1–27 and PACAP1–38 for increasing cellular cyclic
AMP and inositol phosphate were measured. In com-
plete contradiction to predictions of simple receptor the-
ory, the two agonists reversed their relative order of
potency for the two signaling pathways mediated by the
same receptor. Thus, whereas the relative potency for
cyclic AMP was PACAP1–27 PACAP1–38, this order was
reversed for inositol phosphate production (PACAP1–27 
PACAP1–38) (Spengler et al., 1993). These data defini-
tively demonstrated that the two agonists were not
activating the receptor in the same manner but rather
that there is a uniqueness to the activation related to
each agonist that expressed itself as a different bias in
signaling.
The first formal model to account for these digressions
postulated that it was the ligand-receptor complex, not
the receptor, that constituted the minimal recognition
unit for cytosolic elements interacting with the receptor,
in essence what was called the “receptor active state”
made by the ligand (Kenakin, 1995a). This model was
adapted from an earlier one that describes the interac-
tion of a single receptor with two G proteins (Kenakin
andMorgan, 1989). Thus, agonist-selective active states,
formed by different agonists, could bias the activation of
cellular signaling pathways and be functionally selec-
tive. Although originally defined for G protein-receptor
interaction, functional selectivity extends beyond pro-
cesses mediated by G proteins. Another early indication
that ligands could stabilize receptor conformations that
mediated effects beyond G protein activation was the
observation that antagonists, devoid of agonist activat-
ing activity, nevertheless produced active internaliza-
tion of receptors (Roettger et al., 1997; Gray and Roth,
2001). This disproved the notion that antagonists were
just inert ligands that occluded access to the binding site
for endogenous agonists on receptors; this idea will be
developed in later discussion of the classification and
nomenclature of antagonists (section V.C.2.f).
b. Ligand-specific seven transmembrane receptor con-
formations. The observation of differential signaling
has supported the notion that molecules produce ligand-
specific conformations in the cell membrane (Palanche
et al., 2001; reviewed in Kenakin, 2001, 2002a,b, 2003).
In fact, the ability of ligands to stabilize different con-
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formations of 7TMRs has been confirmed directly with a
number of technological approaches, including fluores-
cent probes on receptors (Gether et al., 1995; Ghanouni
et al., 2001; Kobilka and Gether, 2002), plasmon-
waveguide resonance spectroscopy (Hruby and Tollin,
2007; Georgieva et al., 2008), fluorescence resonance
energy transfer studies (Vilardaga et al., 2003, 2005;
Swaminath et al., 2004, 2005; Granier et al., 2007; Lohse
et al., 2008; Zu¨rn et al., 2009), bioluminescence reso-
nance energy transfer studies (Galandrin et al., 2008;
Lohse et al., 2008), circular dichroism (Bane`res et al.,
2005), X-ray crystallography (Okada and Palczewski,
2001), antibody binding (Tutor et al., 2007), site-directed
mutagenesis and molecule modeling (Pellissier et al.,
2009), and kinetic studies (Swaminath et al., 2004). As
mentioned previously, indirect cytosolic signaling
probes have been used for a number of years to detect
ligand-specific receptor conformations. The general idea
is that if ligands stabilize different conformations, then
signaling molecules should detect these effects by differ-
ential engagement of signaling proteins. For example,
experiments such as the transfection of the human cal-
citonin receptor into wild-type HEK cells and HEK cells
cotransduced with Gs protein showed that agonists
such as eel and porcine calcitonin actually reversed their
relative potency in cells enriched with Gs protein
(Watson et al., 2000). These data were best explained by
the postulate that eel and porcine calcitonin stabilize dif-
ferent active state conformations of the calcitonin receptor
and that these had higher affinities for Gs protein.
In general, if it is accepted that ligands stabilize dif-
ferent global ensembles of conformations and that dif-
ferent cytosolic guests (e.g., signaling proteins) interact
with different parts of 7TMRs (Ikezu et al., 1992; Jones
and Hinkle, 2008), then it would be expected that mul-
tiple probe allostery would show probe dependence. For
example, different structural elements of -arrestin,
which itself has been shown to undergo changes in con-
formation with receptor binding (Xiao et al., 2004), have
been shown to interact with different forms of the recep-
tor (Hanson and Gurevich, 2006). Therefore, on a theo-
retical level, agonist-selective stabilization of different
receptor conformations would be predicted to result in
bias in coupling to different cytosolic proteins. In prac-
tice, there has been a great deal of evidence to show
biased agonist effects that are consistent with the sta-
bilization of ligand-specific receptor active states over
the past 15 years (see section V.C.2.b). Only recently has
biased signaling of the MAPK pathway through G pro-
tein and G protein-independent pathways been directly
correlated with unique receptor conformations as mea-
sured by bioluminescence resonance energy transfer
(Galandrin et al., 2008).
One of the more direct methods of demonstrating that
receptors can form more than one active functional state
is the observance of protean agonism. Protean agonists
are ligands that produce a receptor active state that is
capable of initiating signal where there is none by sta-
bilizing a receptor active state that is less efficacious
than the naturally occurring, spontaneously formed con-
stitutive active state (Kenakin, 1995b, 2001). Thus, pro-
tean agonists produce positive agonism in quiescent
nonconstitutive systems and inverse agonism in consti-
tutively active systems. These molecules were named
after the Greek sea-god Proteus (son of Poseidon), who
could change shape at will depending on his environ-
ment and needs (Kenakin, 1995b). Experimental exam-
ples of a protean agonist are dichloroisoproterenol for
-adrenoceptors (Chidiac et al., 1996) and levomedeto-
midine for 2A-adrenoceptors (Jansson et al., 1998).
The selective stimulation of cellular pathways by dif-
ferent agonists acting through a single receptor been
referred to by many names: stimulus trafficking (Kenakin,
1995a), functional dissociation (Whistler et al., 1999),
biased agonism (Jarpe et al., 1998), biased inhibition
(Kudlacek et al., 2002), differential engagement (Man-
ning, 2002), discrete activation of transduction (Gurwitz
et al., 1994), and functional selectivity (Lawler et al.,
1999; Kilts et al., 2002; Shapiro et al., 2003). The term
functional selectivity, coined by the Mailman group as
early as 1994 (Lawler et al., 1994), is a commonly used
term for this effect. Proposed as a universal thermody-
namic mechanism for all 7TMRs (Kenakin, 1995a), it
has been described for many receptors and discussed as
a general receptor mechanism (Gurwitz and Haring,
2003; Hermans, 2003). The list of 7TMRs for which
functionally selective signaling has reported is exten-
sive; for a partial listing, see Table 1. Cytosolic allostery
resulting in differential trafficking of ligand information
can involve different modulator/conduit/guest arrays,
and it is useful to differentiate these for discussion.
In summary, when the conformation of 7TM receptors
is examined, either directly with biochemical or biophys-
ical methods or indirectly through the response of guest
molecules, such as signaling proteins in cells, it is clear
that a wide range of conformational ensembles can be
stabilized by different modulators. Under these circum-
stances, it is not guaranteed that a single assay format
will detect all known effects of a ligand, and it cannot be
assumed that two ligands will produce the same reper-
toire of receptor behaviors that would correspondingly
produce the same array of signals. This latter effect will
now be considered as a system whereby a modulator is
an agonist acting through a receptor to signaling pro-
teins (G proteins, -arrestin etc.) as guests; this can
result in biased agonism.
c. Biased agonism. As preferred ensembles of confor-
mations interact with cytosolic signaling proteins, bi-
ased activation of signaling cascades ensues. The fact
that collections of cytosolic proteins interact with most
7TMRs combined with the notion that regions of pro-
teins change with respect to each other in nonconcerted
ways (i.e., different regions move at different rates;
therefore, an ensemble will never contain identical ter-
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tiary conformations) necessarily leads to the conclusion
that different ensembles will have differential sensitiv-
ity for any collection of signaling proteins in a cell (see
multiprobe allostery). This is the thermodynamic mech-
anism of biased signaling (for reviews, see Kenakin,
2002a,b, 2006, 2007b; Hermans, 2003; Kukkonen, 2004;
Perez and Karnik, 2005). It has been known for some
time that the interaction of -arrestin with 7TMRs is
very important for the cessation of G protein signaling
(Ferguson, 2001; Pierce and Lefkowitz, 2001; Luttrell
and Lefkowitz, 2002) and the internalization of 7TMRs
(by linking receptors to endocytic machinery such as
clathrin and clathrin adaptor activator protein 2) (Good-
man et al., 1996; Laporte et al., 2000, 2002; Kim and
Benovic, 2002; Edeling et al., 2006). However, it has also
become apparent that -arrestin mediates signaling in
its own right (Luttrell et al., 1999; Luttrell and Lefkow-
itz, 2002; Terrillon and Bouvier, 2004; Lefkowitz and
Shenoy, 2005; Luttrell, 2005; Lefkowitz et al., 2006;
Smith and Luttrell, 2006; DeWire et al., 2007). This
latter idea describes a complex between the receptor,
-arrestin, and various cytosolic MAP kinases to form a
“signalsome” that can produce a low-level, long-lasting
cellular signal through activation of ERK1/2. p38 MAPK
and c-Jun NH2-terminal kinase also function as scaf-
folds to connect 7TMR complexes to tyrosine kinase c-
Src, phosphatidylinositol 3-kinase/AKT, and nuclear
factor-B pathways (van Biesen et al., 1996; Claing et
al., 2002; Ga´borik and Hunyady, 2004; Lefkowitz and
Whalen, 2004; Lefkowitz and Shenoy, 2005; Vroon et al.,
2006).
Biased signaling can roughly be divided into the acti-
vation, by an agonist-bound 7TMR, of processes that
produce rapid transient G protein-mediated responses,
low-level, long-lasting -arrestin-mediated responses,
desensitization of response (usually G protein response
largely through -arrestin binding to the receptor)
(Kelly et al., 2008), and removal of the receptor from the
cell surface through the process of internalization. Ago-
nist-mediated internalization of receptors can further be
differentiated by the long-term fate of the internalized
receptors. Although some internalization effects result
in rapid recycling of the receptor back to the surface of
the cell, other ligands induce much longer term removal
and destruction of the receptor from the cell surface (i.e.,
Mack et al., 1998; Ryman-Rasmussen et al., 2007). Thus,
biased agonists produce one or more of these activities to
varying degrees.
Almost all agonists for 7TMRs have been character-
ized through measurement of G protein signals mediat-
ing cell second messengers or calcium. However, because
the measurement of -arrestin signaling effects are be-
coming routine, agonists are now being classified as
actually being biased toward the -arrestin system. For
example, PTH activates extracellular signal-related ki-
nase through separate G protein-related and G protein-
independent pathways. However, analogs of PTH can sep-
arate stimulus through the PTH receptor to these
pathways. For example, ERK1/2 is stimulated primarily
via the G protein pathway by [Trp1]PTHrp-(1–36) and
mainly through the -arrestin-dependent (and G protein-
independent) pathway by PTH-1A [[D-Trp12,Tyr34]PTH-
TABLE 1
Examples of receptors that demonstrate biased agonism
Receptor Reference
PACAP-1 Spengler et al., 1993; Van Rampelbergh et al., 1996
Dopamine D2 Meller et al., 1992; Cordeaux et al., 2001; Mottola et al., 2002; Gay et al., 2004; Urban et al., 2007
Dopamine D1 Ryman-Rasmussen et al., 2005
Histamine H3 Krueger et al., 2005
Muscarinic acetylcholine receptor Akam et al., 2001; Thomas et al., 2008
GLP-1 Jorgensen et al., 2007
Neurokinin1 Sagan et al., 1999
2-Adrenoceptor Seifert et al., 1999; Wenzel-Seifert and Seifert, 2000; Azzi et al., 2003; Galandrin et al., 2008
PTH Takasu et al., 1999; Bisello et al., 2002; Gesty-Palmer et al., 2006
Gonadotropin-releasing receptor Lu et al., 2007
Calcitonin Watson et al., 2000
Adenosine A1 Cordeaux et al., 2000
Adenosine A3 Gao and Jacobson, 2008
-Opioid Keith et al., 1998; Allouche et al., 1999; Whistler et al., 1999; Arttamangkul et al., 2008
5-HT2C Berg et al., 1998; Werry et al., 2005
5-HT2A Kurrasch-Orbaugh et al., 2003
Cannabinoid Bonhaus et al., 1998; Mukhopadhyay and Howlett, 2005; Shoemaker et al., 2005; Bosier et al.,
2008
Protease-activated receptor 1 McLaughlin et al., 2005
Chemokine CXCR2 Hall et al., 1999
2A-Adrenoceptor Kukkonen et al., 2001; Vilardaga et al., 2005; Nikolaev et al., 2006
Bombesin MacKinnon et al., 2001
Metabotropic glutamate Tateyama and Kubo, 2006
Chemokine CCR7 Kohout et al., 2004
Angiotensin IA Wei et al., 2003; Hunton et al., 2005
Somatostatin Liu et al., 2005; Cescato et al., 2006; Engström et al., 2006
Corticotropin-releasing factor type 1 receptor Beyermann et al., 2007
CCR5 Oppermann et al., 1999; Proudfoot et al., 1999; Watson et al., 2005
Melanocortin 4 receptor Nickolls et al., 2005
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(7–34) (Gesty-Palmer et al., 2006)]. Likewise, the Sub-
stance P analog [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance
P and bombesin both activate ERK1/2 through the bomb-
esin/gastrin-releasing peptide receptor. However, the ef-
fects of [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P are per-
tussis-sensitive (indicating a Gi protein dependence of the
effect), whereas the responses to bombesin are not. In fact,
bombesin stimulates the ERK1/2 pathway through a G
protein-independent -arrestin effect (MacKinnon et al.,
2001). Likewise, angiotensin produces activation of G pro-
teins and -arrestin through binding to angiotensin type
1A receptors. However, the angiotensin agonist analog SII
(Sar1,Ile4,Ile8-AngII) (Holloway et al., 2002) is “perfectly
biased” toward producing activation of only the -arrestin
pathway through this receptor (Ahn et al., 2003; Wei et al.,
2003). Other examples of perfect bias for -arrestin activa-
tion can be found in standard -blockers. Thus proprano-
lol, a known inverse agonist for Gs protein interaction
with 2-adrenoceptors (Baker et al., 2003) produces acti-
vation of -arrestin (Azzi et al., 2003; Galandrin et al.,
2008). Similar profiles are observed for carvedilol (Wisler
et al., 2007) and bucindolol (Galandrin et al., 2008). In
addition, just as there is heterogeneity in the G protein
array available for 7TMR interaction, there are data to
suggest that -arrestin is functionally diverse as well
(Shukla et al., 2008). Finally, it should be noted that 7TMR
signaling and behavior can also be mediated by other cy-
tosolic proteins in addition to G proteins and -arrestin
(Bockaert and Pin, 1999; Heuss and Gerber, 2000; Brady
and Limbird, 2002; Bockaert et al., 2004; Lanier, 2004;
Gavarini et al., 2006; Sun et al., 2007b). Current data for
agonist bias most often report effects seen with synthetic
agonists, but there is at least one 7TMR in which it is
operative for natural ligands. CCL19 and CCL21, two nat-
ural agonists for the CCR7 chemokine receptor, both pro-
duce G protein activation but differ in that only CCL19
(not CCL21) causes receptor agonist-dependent phosphor-
ylation and recruitment of -arrestin to terminate the G
protein stimulus (Kohout et al., 2004).
G protein-dependent and -independent (-arrestin-
mediated) signals converge to produce ERK phosphory-
lation (Kim et al., 2009), the source of which often can be
differentiated kinetically (Ahn et al., 2004 Gesty-Palmer
et al., 2006; DeWire et al., 2007). Specifically, the G
protein response is rapid and transient, whereas the
-arrestin response is sustained, and these two signals
can have different consequences for the cell (see section
V.C.3). Biochemical information about the origin and
control of these two signals Leads to the study of factors
that emphasize different signaling pathways in cells,
hopefully for therapeutic advantage. In general, inter-
actions of receptors with multiple signaling proteins cre-
ate the ideal conditions for biased agonism if selective
receptor conformations are stabilized by different ago-
nists. On a theoretical level, biased effects should be
anticipated and signaling identical to endogenous natu-
ral agonists should not be expected.
In addition to acute cellular events, there are other
long-term consequences to 7TMR-mediated signaling.
For example, the generation of  subunits from G pro-
tein activation also can produce cross-activation of path-
ways and ligand-dependent nuances in cellular response
(Rives et al., 2009). Yet an additional consequence of
signaling through agonists can be observed upon chronic
activation, which involves the restructuring of the ago-
nist signaling system. For example, regulation of G pro-
teins can result from agonist activation as in the up-
regulation of G12 and down-regulation of Gi3 proteins
by -opioid receptors in Chinese hamster ovary cells (Xu
et al., 2008). Likewise, the ligand-specific expression of
-arrestin2 and G protein receptor kinase (GRK) 2 is
modulated through receptor by activation by etorphine
but not morphine (Narita et al., 2006; Zheng et al.,
2008).
One of the major mechanisms of coding for functional
selectivity of 7TMRs is the phosphorylation of the li-
gand-stabilized receptor by GRKs (Pitcher et al., 1998)
at the C-terminal (Mendez et al., 2000; Seibold et al.,
2000; Kara et al., 2006; Liu et al., 2008) and/or second
intracellular loops (Nakamura et al., 1998; Kim et al.,
2001) of 7TMRs. This “barcoding” (Zidar et al., 2009) of
the receptor by GRK phosphorylation forms the link
between the agonist (as it stabilizes unique 7TMR con-
formations) and the rest of the cytosolic machinery.
In summary, the fact that a number of signaling pro-
teins interact with the receptor at the cytosolic face of
the cell membrane at different binding loci opens the
possibility of differential interaction of the receptor with
these signaling proteins because it forms different con-
formations. Because different ligands can stabilize dif-
ferent receptor conformations, this naturally leads to the
conclusion that these same ligands differentially acti-
vate cell signaling; i.e., they can bias the activation to
some pathways over others. This type of differential
signaling can involve different G proteins, direct activa-
tion of -arrestin as a signaling molecule, or other cel-
lular components such as GRK.
d. Biased antagonism. As discussed in the section on
guest allostery (section V.A.1), modulators produce per-
missive effects by virtue of the fact that they bind to
their own site on the receptor and allow other ligands
(i.e., agonists) to bind to the receptor as well. This can
produce direct effect such as antagonism or potentiation,
but it can also alter the direct effects of the cobinding
guest ligand. Thus, the agonist signaling profiles of ago-
nists can be altered by allosteric modulators; this, in
turn, can produce a bias in the activation pattern of the
agonist. Such effects are referred to as biased antago-
nism. It should be noted that this term specifically de-
scribes the imposition of biased agonism upon an agonist
interacting with the receptor after antagonist binding
and does not refer to any direct effects (such as -arres-
tin activation or internalization) that the antagonist
may possess as well.
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In terms of imposing biased agonism on natural ago-
nists, N-tosyltryptophan, the allosteric modulator for
CRTH2 receptors, causes the natural agonist prosta-
glandin D2 to change its signaling pattern from activa-
tion of Gi and -arrestin to activation of Gi alone, with no
concomitant -arrestin interaction (Fig. 8) (Mathiesen et
al., 2005). Likewise, the natural neurokinin 2 receptor
agonist neurokinin A activates Gs and Gq proteins, but
the allosteric modulator N,N-(2-methylnaphthyl-ben-
zyl)-2-aminoacetonitrile (LP1805) changes this pattern
to one of enhanced Gq and blockade of Gs activation
(Maillet et al., 2007). The peptide antagonist of the IL-1
receptor 101.10 blocks certain IL-1 signaling pathways but
not others (Quiniou et al., 2008). Likewise, a striking dis-
parity in the efficacies of a range of antipsychotic dopamine
D2 antagonists in blocking G protein-mediated effects and
-arrestin has been described previously (Masri et al.,
2008). In addition, the antagonist N-(2-adamantyloxy)car-
bonyl--Me-D-Trp-D-cis-Hyp-(o,p-dichlorophenol) (RB213)
has been reported to show pathways for selective antago-
nism for type 2 cholecystokinin receptor-mediated inositol
phosphate formation and arachidonic acid release (Pom-
mier et al., 1999). In general, any therapeutic situation in
which biased agonism may be beneficial qualifies also for
intervention with a biased antagonist and this opens new
vistas for therapy (see section V.C.3).
e. Functional selectivity and newdrug discovery. The dis-
covery that ligands can stabilize unique receptor confor-
mations with pharmacologically relevant properties theo-
retically increases the scope for therapeutically targeted
selective drug effect (see section V.C.3). Progress in the
characterization of functional selectivity has largely been
the result of being able to monitor multiple signaling path-
ways in cells and observing differential activation of those
pathways by various ligands. The ultimate result of bi-
ased agonism and/or biased antagonism is a phenotypic
response that can be unique to a given cell. The first step
in the prosecution of this mechanism for new drug dis-
covery is to have the ability to detect the effect. To this
end, there has been vast progress in technology in phar-
macological assay systems. One of the most facile ap-
proaches has been the return to whole-system real-time
response reading of pharmacologic response not from
isolated tissues but rather from human cells in culture.
Recent technological advances have expanded possi-
ble modes of detection of receptor function. The impor-
tance of 7TMR and -arrestin association for function-
ally selective effects is obvious, and with this realization
has come an increase in the technology available to
directly measure these effects. A great deal of informa-
tion is obtained from high-content assays based on im-
aging techniques that use fluorescent signals to yield
information about receptor interaction with -arrestin
and subsequent movement of the receptor/-arrestin
complex within the cytoplasm (Milligan, 2003; Lefkowitz
and Whalen, 2004; Fredriksson and Schio¨th, 2005).
These responses can be monitored directly through ob-
servation of receptor/-arrestin green fluorescent pro-
tein complexes (Oakley et al., 2002; Ghosh et al., 2005;
Ross et al., 2008; Hanson et al., 2009; van der Lee et al.,
2009), with bioluminescence resonance energy transfer
(Milligan, 2004; Hamdan et al., 2005), with enzyme frag-
ment complementation (Olson and Eglen, 2007; Zhao et
al., 2008; van der Lee et al., 2009), or with protease-
activated transcriptional reporter genes (Barnea et al.,
2008; Verkaar et al., 2008). Green fluorescent protein
and immunofluorescence-based technologies can also be
multiplexed to gain multiple readouts from the same cell
to compare signaling pathways (Henriksen et al., 2008).
There also have been tremendous advances in tech-
nology for the observation of integrated whole-cell phar-
macologic responses. Resonant waveguide grating tech-
nology has led to the use of optical biosensors that can
measure dynamic mass redistribution signals from
whole cells (Fang et al., 2006). This technology can de-
tect interactions of 7TMRs with many cytosolic signaling
molecules, such as G proteins and -arrestin, at a depth
of 150 to 200 nm within the cell and can also detect
receptor internalization. The resulting dynamic mass
redistribution signal is a noninvasive cell-based technol-
ogy that can measure virtually any receptor activation
in any cell type in systems such as the Epic (Fang et al.,
2005a,b). The responses are obtained in real time and
have characteristic kinetic patterns that can be used to
identify specific signaling pathways. This technique has
been applied to the detection and quantification of func-
tional selectivity in live whole-cell assays (Cunningham
et al., 2004; Fang, 2006; Yu et al., 2006; Fang and Ferrie,
2008). Another type of technology that can be used for
the same purpose employs alterations in the electrical
Orthosteric Antagonist
Biased Antagonism
Biased Antagonist
Antagonist
N-α-T
G-Protein G-Proteinβ-Arrestin β-Arrestin
PDG2 PDG2
FIG. 8. Two contrasting mechanisms of receptor antagonism. A, or-
thosteric antagonists block agonist activation of the receptor and all
functions mediated by that activation are uniformly inhibited. For exam-
ple, prostaglandin D2 is the endogenous agonist for CRTH2 receptors
causing activation of Gs protein and -arrestin. An orthosteric antago-
nist blocking PDG2 binding to the receptor would block both pathways.
B, the allosteric modulator N--tosyltryptophan (N--T) blocks the Gs
protein activation of CRTH2 through PDG2 but still allows the agonist to
active -arrestin (Mathiesen et al., 2005).
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impedance of layers of cells in culture caused by recep-
tor-mediated changes in cell mass redistribution (Ver-
donk et al., 2006; McGuinness, 2007; Peters et al., 2007;
Shiau et al., 2008; Peters and Scott, 2009). In general,
whole-cell responses are the result of the integration of
numerous pathway activations and as such are ideal for
detecting bias in signaling. These formats also are pref-
erable for detecting agonist phenotypes that will be rel-
evant in the therapeutic situation. The use of these
techniques in primary cells adds a further advantage to
this approach.
There are two points of control in functionally selec-
tive system; the receptor conformation and the cell. Both
of these furnish the control units for allostery, namely
the ligand structure (as the modulator) and the signal-
ing molecules [as the guest(s)]. The ligand control by
chemical structure is ideal for drug discovery because it
theoretically enables medicinal chemists to control the
receptor conformation stabilized and subsequently the
signaling pathway selectively activated. The second fac-
tor, however, is deleterious to orderly drug discovery
because it imposes a cell type dependence on function-
ally selective effects that is difficult to control in discov-
ery programs. This is because new drug candidates usu-
ally are tested and optimized in cell systems different
from the therapeutic ones.
There are a number of phenotypic drug responses
associated with cell types that are not specifically as-
cribed to mechanisms but are nevertheless noted in the
literature (i.e., levomedetomidine for 2A-adrenoceptors
(Jansson et al., 1998; Kukkonen et al., 2001), isopros-
tane 8-iso-prostaglandin F for thromboxane A2 receptors
(Weber and Markillie, 2003), and quinpirole for dopa-
mine D3 and D2 receptors (Zaworski et al., 1999; Alberts
et al., 2000). In addition, cells can adjust their signaling
capability according to their needs through control of re-
agents required for receptor phosphorylation [i.e., through
GRKs (Lohse, 1993; Zamah et al., 2002; Ribas et al., 2007;
Tobin et al., 2008) or protein kinase A (Daaka et al., 1997;
Tobin, 2008)] and internalization. For instance, immune
cells dynamically regulate GRK and arrestin levels accord-
ing to levels of inflammation (Chuang et al., 1992; Vroon et
al., 2006). This can lead to differences in receptor phos-
phorylation “barcoding” that can go on to target receptors
for different signaling pathways. Cell-type dependence is
observed for phosphorylation of different residues in soma-
tostatin type 2A receptors when studied in Chinese ham-
ster ovary, pituitary, and GH4C1 cells (Liu et al., 2009).
Likewise, different cell type-dependent phosphorylation of
muscarinic m3 receptors has been observed (Torrecilla et
al., 2007). Cell variability with functionally selective effects
has also been described in terms of differences in recep-
tor-G protein relative stoichiometry (Kenakin, 1997a;
Gonza´lez-Maeso et al., 2002; Ernst et al., 2007; Philip et
al., 2007). For example, the 3-adrenoceptor ligands (R,R)-
5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]-pro-
pyl]1,3-benzodioxole-2,2-decarboxylate (CL316243) and
3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-
ylamino]-2S-2-propanol oxalate (SR59230A) both elevate
cyclic AMP and activate ERK1/2 and p38MAPKphosphor-
ylation but with reverse potencies for these pathways (they
are functionally selective) (Sato et al., 2007). However, the
dominant pathways activated by each agonist change with
expression level of 3-adrenoceptors, with a resulting dif-
ference in the overall potency of these ligands in producing
cellular activation (Michel and Alewijnse, 2007; Sato et al.,
2007).
Levels of GRKs are high and dynamically regulated in
immune cells (Chuang et al., 1992; Mak et al., 2002). In
addition to intrinsic differences in GRK and -arrestin
levels in different cell types, levels of these proteins also
have been shown to vary in disease. For example, down-
regulation of GRK2 and GRK6 has been observed in
patients with rheumatoid arthritis and multiple sclero-
sis (Lombardi et al., 1999; Giorelli et al., 2004; Vroon et
al., 2005) and in rat immune cells from rats with adju-
vant arthritis (Lombardi et al., 2001; Vroon et al., 2003).
Overexpression of GRK2 in vascular smooth muscle has
been shown to lead to hypertension and cardiac hyper-
trophy (Eckhart et al., 2002). Because receptor desensi-
tization, phosphorylation, and internalization are known to
be modulated by expression levels of GRKs and -arres-
tin (Me´nard et al., 1997; Schlador and Nathanson,
1997), these effects can lead to cell-type dependence for
biased ligands.
One behavior of 7TMRs that has been shown to be
particularly cell-type dependent is receptor internaliza-
tion. For example, CB1 cannabinoid receptors have been
shown to have varying patterns of phosphorylation lead-
ing to different internalizing behavior in HEK293 and
AtT20 cells (Daigle et al., 2008). Receptor internaliza-
tion has been extensively studied for opioid receptors,
where it has been shown that opioid receptor internal-
ization can be cell-type dependent (Zhang et al., 1998;
Whistler and von Zastrow, 1999; Bailey et al., 2003;
Bohn et al., 2004; Koch et al., 2005). This poses a prac-
tical problem for prediction of the propensity for new
opioid ligands to internalize receptors. It is noteworthy
that Groer et al. (2007) have shown that opioid receptors
in HEK293 cells do not internalize with morphine or
herkinorin activation. However, after transfection of
HEK293 cells with GRK2 and -arrestin2, morphine
does internalize opioid receptors, but herkinorin still
does not. This may suggest a characteristic property of
the morphine and herkinorin scaffolds, namely that
morphine can lead to receptor internalization in cells
with sufficient reagents to support the process (GRK2
and -arrestin) whereas herkinorin will not internalize
receptors in any cell type irrespective of the levels of
GRK and -arrestin. Thus, the testing of opioid agonists
in GRK2-transfected cells could function as characteris-
tic assay for the detection of opioid receptor internaliz-
ing activity in ligands.
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The data with morphine and herkinorin suggest an
approach to control for, or at least predict, cell-type
dependence would be through the use of transfection for
purpose assays. In theory, these could be used to identify
characteristic properties of functionally selective ligands
as predictors of activity in different cell types (Kenakin,
2009b). The association of GRKs with general effects on
7TMRs (Kim et al., 2005; Ren et al., 2005) [e.g., GRK2,3
for desensitization and GRK5,6 for signalsome response
(Reiter and Lefkowitz, 2006)] opens the possibility of
designing biased assays to detect selectivity for desensi-
tization and non G protein mediated -arrestin-based
signaling. The actual association of the type of GRKwith
biochemical effects on the receptor may be receptor-type-
dependent, because the rule of GRK2 for desensitization
and GRK5/6 for -arrestin signaling does not hold true
for all receptor and cell types. For example, overexpres-
sion of GRKs 2, 5, and especially 6 has been shown to
cause leukotriene B4 receptor desensitization in Cos-2
cells (Gaudreau et al., 2002).
For functional selectivity to be therapeutically ap-
plied, structure-activity relationships for biased signal-
ing must be understood. A prerequisite for this is a scale
for quantifying bias. A useful starting point is to de-
scribe agonism in terms of the Black/Leff operational
model, in which affinity (denoted as KA, the equilibrium
dissociation constant of the agonist-receptor complex)
and efficacy (denoted as , a parameter encompassing
both the efficacy of the agonist and the sensitivity of the
system) (Black and Leff, 1983; Black et al., 1985). Ago-
nist bias must be described both in terms of affinity and
efficacy because both can change with allosteric modu-
lation within descriptions of agonism with the opera-
tional model (Kenakin, 2009a). Figure 9 shows the cal-
cium transient response to a range of agonists for the
calcitonin receptor in wild-type HEK293 cells and cells
stably transfected to increase levels of Gs protein. It
can be seen from Fig. 9, A and B, that the potency ratios
of the agonists differ in the different cellular back-
ground(s). For each cell background, values of (/KA),
relative to a chosen standard for the system, which in
this case is amylin, are calculated to quantify the rela-
tive ability of each agonist to produce response (/KA is
referred to as the transduction ratio). For wild-type
HEK cells this is 19.05:5.5:1.91:1 for eel calcitonin 
porcine calcitonin  rat calcitonin  amylin. It is note-
worthy that in Gs-transfected cells, this relative order
changes to 100:26:21.9:1 for porcine calcitonin  rat
calcitonin eel calcitonin amylin. Thus, the change in
only cell background produces a fundamental change in
relative agonist potency ratios. A comparison of relative
/KA values can now be used to compare across cell type
(Fig. 9, columns labeled “bias” in table). It can be seen
that whereas the cotransfection of Gs into the HEK cell
have minimal effect on the transduction ratio for eel
calcitonin (relative to amylin) but considerable effect on
the agonism produced by porcine calcitonin and rat cal-
citonin. Because relative /KA scales theoretically cancel
system effects, calculated bias could be used by medici-
nal chemists to systematically explore agonist bias in a
chemical series. The bias observed for these agonists has
been proposed to be due to the stabilization of different
active states of the calcitonin receptor with differing
relative affinity for Gs protein (Watson et al., 2000). In
FIG. 9. Differences in relative agonist activity with changes in cellular background. A, calcium transient response for activation of human
calcitonin receptors transfected into HEK293 cells by eel (F), porcine (E), and rat (Œ) calcitonin and rat amylin (‚). B, responses to the same agonists
in HEK293 cells transfected with Gs protein. Note that the relative potencies of the agonists change. The table shows the activity of the agonists in
terms of their log transduction ratios [Log (/KA)] values in the two cell hosts and their relative activity in terms of the reference agonist amylin
[Log(/KA) values]. A measure of the relative effect of Gs-transfection on each agonist is given as the bias. Data from Watson et al. (2000).
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terms of this hypothesis, these data indicate that rat and
porcine calcitonin have a greater bias for activating Gs
protein (over other G proteins) than do amylin and eel
calcitonin (bias in order of increasing relative interac-
tion with Gs protein as porcine calcitonin  rat calci-
tonin  rat amylin  eel calcitonin).
Another useful measurement for describing agonist
effect has been given by Ehlert (2005) and Tran et al.
(2009). Specifically, when dose-response relationships
can be described by a rectangular hyperbola, the maxi-
mum response (denoted Max) divided by the EC50 (the
molar concentration producing half-maximal effect) de-
scribes the ratio of the affinity and the efficacy of the
agonist [referred to as the activity ratio (Max/EC50)]. It
can be shown that even when a rectangular hyperbolic
relationship between concentration and response is not
the case, Max/EC50 values are still a useful measure of
agonism. Of note is the fact that Max/EC50 values are
unique for the particular response pathway being mea-
sured; therefore, they serve to characterize the ability of
a given agonist to produce activation of a given signaling
pathway. Therefore, if two pathways are measured, the
relative activation of one (as a function of the activation
of the other) can be used to determine signaling prefer-
ence to yield a measure of bias.
It is interesting to note the subtle structure-activity
relationships that have been reported for biased ligands.
For example, a single substitution of an oxygen for a
nitrogen in the herkinorin chemical scaffold converts an
opioid receptor agonist that activates G proteins and
causes the  opioid receptor to associate with -arrestin
and become internalized to the cytoplasm to an agonist
that activates only G protein but does not cause inter-
actions with -arrestin or receptor internalization
(Tidgewell et al., 2008). Within a series of phenylethyl-
amines, a considerable bias for association of 2-adreno-
ceptors with -arrestin was observed for selective com-
pounds containing an ethyl substitution of the -carbon
(Drake et al., 2008). Stereoisomers of fenoterol differen-
tially activate Gs and Gi proteins in rat cardiomyocytes
(Woo et al., 2009). Likewise, 5-HT2C (Miller et al., 2000)
and dopamine D2 (Gay et al., 2004) ligands demonstrate
more than 100-fold differences in bias with relatively
small changes in chemical structure, and no change in
overall affinity. In general, it should be noted that bias
within agonists does not require large differences in
chemical structure.
f. Functional selectivity and drug nomenclature. The
ability to see multiple signaling pathways linked to re-
ceptors has revealed the lack of concordance of receptor
behaviors when bound to ligands. When Stephenson
(1956) defined “efficacy,” the only indication of receptor
activation available in his experiments was contraction
of guinea pig ileum. Now we are able to visualize sepa-
rate components of whole-cell respons, and the data
show previously unknown diversity. Thus, for function-
ally selective biased agonists, it can be seen that some
cellular pathways are activated and some are not (e.g., G
protein versus -arrestin). This is posing interesting
problems for the nomenclature of drugs (Kenakin, 2008).
The canonical definitions of agonist and antagonist are
ligands that produce activation of cells and inhibition of
ligand-mediated activation, respectively. However, it is
now known that ligands can be antagonists for some
pathways and agonists for others (Azzi et al., 2003;
Wisler et al., 2007, Galandrin et al., 2008); i.e., pro-
pranolol, carvedilol, and bucindolol block 2-adreno-
ceptor-mediated elevations in cyclic AMP but activate
ERK through -arrestin. Likewise, a PTH inverse agonist
for Gs protein activation [D-Trp
12,Tyr34PTH(7–34)]
(Gardella et al., 1996) also produces a positive signal via
-arrestin in the absence of Gs or Gq stimulation (Gesty-
Palmer et al., 2006). Even within the realms of activation
of G-protein pathways, conflicting effects are observed.
For example, the cannabinoid CB1 receptor agonist
desacetyl levonantradol is a positive agonist for Gi1 and
Gi2 but an inverse agonist for Gi3; similarly, the CB1
ligand methanandamide is an inverse agonist for Gi1
and Gi2 and a positive agonist for Gi3 (Mukhopadhyay
and Howlett.2005). In addition, the 5-HT2C ligand
6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyri-
din-3-ylcarbamoyl]indoline (SB242084) is an inverse ag-
onist for Gi protein-mediated phospholipase-2 arachi-
donic acid release and a positive agonist for
phospholipase C-mediated inositol phosphate produc-
tion (De Deurwaerde`re et al., 2004). In addition, many
antagonists have been shown to actively internalize re-
ceptors. Such divergences in efficacy have been used to
propose that efficacy be considered to be “pluridimen-
sional”; i.e., ligands may have a range of different effi-
cacies to cause a range of receptor behaviors (Galandrin
and Bouvier, 2006).
The classification of drugs through their behaviors in
cellular systems (e.g., full agonist, partial agonist, etc.)
has long been known to be a poor practice simply be-
cause of the ability of cellular systems to change these
behaviors with factors such as receptor density or sig-
naling components. This has now been made clearly
apparent by the additional behaviors that ligands can be
seen to have in addition to simple cellular agonism.
These behaviors can serve to modify primary behaviors
and, in some cases, offer directly opposing behaviors
(positive versus inverse agonism). These factors neces-
sarily suggest drug classifications and nomenclatures
more closely associated with pharmacologic processes.
It also opens the possibility of complex pharmacolog-
ical patterns of effect that could lead to cell phenotypic
behavior.
3. Therapeutic Application of Functional Selectivity.
Many 7TMRs mediate pleiotropic signaling, in many
cases through multiple G proteins (see below). Selection
of some of these pathways over others at the G protein
level has been postulated as a means of obtaining ther-
apeutically favorable signaling bias in agonists. For ex-
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ample, activation of thyrotropin (thyrotropin-stimulat-
ing hormone) receptors leads to thyroid growth and
differentiation through activation of Gs protein, whereas
activation of Gq protein is required for stimulation of
thyroid synthesis (Vassart and Dumont, 1992). Under
these circumstances, selective stimulation of thyroid
hormone could be achieved through selective Gq protein
activation. Likewise, -Adrenoceptor agonists are known to
couple to Gs protein to elevate and Gi proteins to reduce
cardiac cell cyclic AMP. Gi-mediated decreases in cyclic
AMP production are accentuated in congestive heart
failure (Xiao et al., 2003), and the balance of cell death
and survival in this disease is related to the relative
-adrenoceptor agonist-induced activation of Gs and Gi
protein (Shizukuda and Buttrick, 2002). The fact that
different -adrenoceptor agonists have differential bias
toward the Gs and Gi signaling pathways (Po¨nicke et al.,
2006) suggests that control of selective signaling for this
receptor may be useful in the treatment of congestive
heart failure. Likewise, activation of histamine H1 re-
ceptors can lead to elevation of cyclic AMP and inositol
phosphate and activation of phospholipase C (Hill et al.,
1997). Studies with the biased histamine receptor agonist
(1R,3S)-()-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahy-
dronaphthalene (Moniri et al., 2004) suggest that a selective
activation of adenylate cyclase in the brain (of possible
value in the treatment of neuropsychiatric and neurode-
generative disorders involving catecholamine transmis-
sion) could be produced without the debilitating hista-
mine-mediated allergic responses and hyperalgesia
(Galeotti et al., 2004).
In addition to multiple G protein coupling, 7TMRs can
couple to other signaling proteins, a common motif being
activation of G proteins to produce rapid transient sig-
naling and activation of -arrestin, which then can serve
as a scaffold for MAP kinases to produce long-term,
low-level signaling. In most cases, natural hormones
and transmitters cause activation of all of these path-
ways, but there are examples in which selection of sig-
naling in disease can lead to improved therapeutic ef-
fect. For example, nicotinic acid activation of the
GPR109 receptor is effective in lowering triglycerides
and elevating high-density lipoprotein (Canner et al.,
1986; Pike, 2005). However, serious cutaneous flushing
limits the use of nicotinic acid as an antilipolytic (Pike,
2005). Studies in GPR109 containing human cells with
nicotinic acid have identified a cyclic AMP lowering ef-
fect as a result of activation of Gi protein and an activa-
tion of cytosolic phospholipase A2 as a result of -arres-
tin 1 binding to the receptor (Walters et al., 2009). This
latter effect is related to arachidonate release, a precur-
sor to prostaglandin D2, which is a potent cause of cu-
taneous flushing. Studies in -arrestin-null mice show
beneficial effects of nicotinic acid on serum-free fatty
acid levels but reduced flushing indicating that an ago-
nist of GPR109, which was devoid of effects on -arrestin
(biased toward Gi protein activation), could be a superior
treatment for dyslipidemia (Walters et al., 2009). It is
noteworthy that a series of pyrazole GPR109 receptor
agonists devoid of the ability to internalize GPR109 and
activate ERK fail to induce flushing (Richman et al.,
2007).
The activation of 2-adrenoceptors results in a bene-
ficial hypotensive response in hypertension but also an
unwanted sedation (Kukkonen, 2004). This latter effect
can be assessed through observation of reduced coordi-
nation and balance in the rotorod test in mice. The
resistance to impairment of rotorod coordination to the
2-adrenoceptor agonist 5-bromo-N-(4,5-dihydro-1H-
imidazol-2-yl)-6-quinoxalinamine (UK-14,304) in -arres-
tin 2 knockout mice suggests that sedation may be related
to the -arrestin signaling pathway (Wang et al., 2004).
These data further suggest that an 2-adrenoceptor biased
agonist devoid of -arrestin 2 stimulation properties
may be a therapeutic improvement (Schmid and Bohn,
2009).
Another case in which a reduced spectrum of agonism
has been proposed to be therapeutically advantageous is
in the treatment of schizophrenia with the antipsychotic
aripiprazole. Specifically, the selectively reduced ability
of this partial agonist to produce MAPK phosphorylation
(versus inhibition of cyclic AMP accumulation and ara-
chidonate release) coupled with its lack of ability to
cause internalization of receptors has been proposed as a
biased agonist profile responsible for the therapeutic
superiority of aripiprazole in the clinic (Grady et al.,
2003; Urban et al., 2007).
Selective -Arrestin signaling also has been associ-
ated with possible beneficial therapeutic effect. For ex-
ample, PTH regulates calcium homeostasis and bone
metabolism, and agonism at the level of the PTH recep-
tor theoretically should produce useful effects in osteo-
porosis. Specifically, intermittent administration of
PTH can increase bone mass by stimulating osteoblasts.
However, PTH also can cause stimulation of bone re-
sorption (a negative effect in osteoporosis) through the
coupling of osteoblasts to osteoclasts. In mice devoid of
-arrestin 2, PTH does not stimulate bone formation or
increase the number of osteoclast cells (Ferrari et al.,
2005). These data suggest that an improved beneficial
effect of PTH stimulation could be obtained in osteopo-
rosis through selective activation of -arrestin 2 (Schmid
and Bohn, 2009). Data showing that analogs of PTH can
produce selective stimulation of G protein and -arrestin
pathways (Bisello et al., 2002; Gesty-Palmer et al., 2006)
offers the promise of possibly improved therapy of osteo-
porosis through biased agonism (Gesty-Palmer et al.,
2009).
There is considerable evidence to show that ligand-
induced receptor internalization may limit therapeuti-
cally relevant chronic agonism. For example, opioids
demonstrate diversity in their ability to internalize opi-
oid receptors. Enkephalins avidly internalize receptors,
whereas morphine produces cell-type-dependent and
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variable internalization (Keith et al., 1998). This effect is
attributed to the inability of morphine to induce receptor
internalization in some cell types (Zhang et al., 1998).
Opioid ligands such as herkinorin, which is biased to-
ward producing even less -arrestin receptor interaction
than morphine (Groer et al., 2007; Xu et al., 2007), may
provide the key to opioid receptor-mediated analgesia
with less concomitant desensitizing effect (Varga et al.,
2004). It is noteworthy that it has been shown that the
beneficial analgesic effects of morphine are enhanced
and prolonged in -arrestin 2 knockout mice (Bohn et
al., 1999; Raehal et al., 2005). These data are consistent
with the notion that -arrestin association of opioid re-
ceptors leads to desensitization and receptor internaliza-
tion. In addition, the negative effects of morphine (respi-
ratory depression, constipation) are dramatically
decreased in knockout mice, suggesting that -arrestin 2
activation by morphine is associated with these negative
effects as well. Another therapeutic area in which receptor
internalization may be important in is the therapy of Par-
kinsonism. Specifically, the dopamine agonist (1R,3S)-3-
(1-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-
1H-2-benzopyran (A-77636) has been shown to be limited
as a therapy for Parkinson’s disease (Lin et al., 1996), an
effect hypothesized to be related to its powerful and pro-
longed (48 h) internalization of dopamine D1 receptors
(Ryman-Rasmussen et al., 2007).
On the other hand, association of receptors to -arres-
tin not only mediates receptor desensitization and inter-
nalization but also can produce G protein-independent
activation of extracellular signal-regulated kinases,
which may, in turn, be therapeutically beneficial. One of
the most striking examples of possible delineation of
beneficial and deleterious effects of these pathways is
seen for the angiotensin receptor (Fig. 10). Angiotensin
has been shown to produce a range of effects on the
cardiovascular system relating to its ability to induce Gq
protein activation of phospholipase C, AT1 receptor
phosphorylation by GRKs, and recruitment of -arrestin
to both internalize the receptor and produce G protein-
independent signaling (Anborgh et al., 2000; Ahn et al.,
2003; Violin et al., 2006). Although the Gq protein-me-
diated effects of angiotensin II can lead to hypertension
and other deleterious cardiovascular effects, selective
activation of -arrestin may be beneficial both through a
modulatory effect on G protein signaling by angiotensin
II. An interesting effect is observed with SII, a -arres-
tin biased agonist of the AT1 receptor. Specifically, this
agonist causes AT1-receptor association with -arrestin
with no concomitant Gq protein effect (Holloway et al.,
2002; Wei et al., 2003; Ahn et al., 2004). In contrast, SII
blocks Gq activation by angiotensin II and produces a
separate -arrestin-mediated antiapoptotic effect (Re-
vankar et al., 2004; Rajagopal et al., 2005; Violin and
Lefkowitz, 2007).
Another realm in which limitation of signaling has
been proposed for therapeutic advantage is in the use of
biased antagonists. For example, the blockade of the
angiotensin AT1 receptor is an extensive strategy in the
treatment of hypertension; cardiac hypertrophy, failure,
and arrhythmia; and diabetic nephropathy. However,
most of these effects are related to blockade of the AT1-
mediated activation of G proteins (i.e., Gq protein-depen-
dent vasoconstriction and hypertrophic growth), whereas an-
giotensin-mediated activation -arrestin 2 has been
associated with cardioprotective responses (Hunton et
al., 2005; Zhai et al., 2005; Rajagopal et al., 2006). There-
fore, a functionally selective AT1 receptor antagonist
that blocked Gq protein activation but allowed -arres-
tin 2 activation could be a superior therapy (Aplin et al.,
2009). Another variation of AT1 receptor biased antago-
nism relates to activation of -arrestin 1. In this case,
angiotensin activation of -arrestin 1 has been associ-
ated with harmful up-regulation of the aldosterone sys-
tem, leading to promotion of postmyocardial infarction,
adverse cardiac remodeling, and progression of heart
failure (Weber, 2001; Connell and Davies, 2005; Marney
and Brown, 2007). Therefore, antagonism of AT1 activa-
tion of -arrestin 1 may have selectively beneficial ef-
fects in cardiovascular therapy (Lymperopoulos et al.,
2009).
The antagonism of serotonin receptors is a very im-
portant aspect of therapy for depression and schizophre-
nia. Serotonin pleiotropically activates signaling path-
ways, some of which (for example, the -arrestin system)
may be selectively associated with visual and auditory
hallucinations (Cussac et al., 2008). It has been postu-
lated that biased antagonism of the serotonin system in
the central nervous system may produce advantageous
Endogenous Agonist
Biased Agonism
Biased Agonist
Angiotensin SII
G-Protein
β-Arrestin
Beneficial Effect(s)?
e.g., cytoprotection?
Deleterious Effect(s)?
e.g., ↑Blood Pressure
G-Protein
β-Arrestin
Beneficial Effect(s)?
e.g., cytoprotection?
Deleterious Effect(s)?
e.g., ↑Blood Pressure
FIG. 10. Biased agonism at the angiotensin II receptor. The natural
ligand angiotensin II produces activation of G proteins, which can pro-
duce a deleterious pressor response in hypertension and heart failure and
also stimulates -arrestin to initiate ERK, Akt, and phosphatidylinositol
3-kinase signals, which could be cytoprotective. The biased agonist SII
produces only activation of -arrestin to induce cytoprotection but not
pressor response. Moreover, receptor occupancy of the receptor by SII
prevents activation by endogenous angiotensin (the receptor is blocked),
thereby further protecting against endogenous pressor response. Data
from Violin and Lefkowitz (2007).
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therapeutic effect (selective effects on hallucinations);
this is currently under investigation (Schmid et al.,
2008). Likewise, the association of serotonin receptors
with the cytosolic phosphatase with tensin homology has
been linked with propensity for addiction (Ji et al.,
2006). Therefore, a ligand that selectively interferes
with this interaction may be beneficial in the treatment
of addiction.
There is no reason a priori to believe that improved
therapeutic profiles should result only from reduction in
signaling capability. Analogs of Substance-P such as SP-D
([D-Arg1,D-Phe5,D-Trp7,8,Leu11]substance P) and SP-G
([Arg6,D-Trp7,9,N-Me-Phe8]substance P(6–11)) gain valu-
able antitumor activity through addition of a biased
activation of Gi proteins in small-cell lung cancer (Mac-
Kinnon et al., 2005), which is a particularly aggressive
cancer characterized by aberrant tumor expression of
receptors for gastrin-releasing peptide and arginine va-
sopressin (Carroll et al., 1999; Jensen et al., 2001);
blockade of these receptors inhibits the mitogenic and
morphogenic effects of these neuropeptides. However, it
has been proposed that the biased stimulating effects of
SP-D and SP-G (Jarpe et al., 1998) [i.e., activation of
ERK signaling (MacKinnon et al., 2001; Djanani et al.,
2003)] in addition to blockade of gastrin-releasing pep-
tide and arginine vasopressin produces the unique anti-
proliferative properties to SP-D and SP-G (MacKinnon
et al., 2005).
It has been shown that, in addition to blockade of
-adrenoceptor G protein activation, some -blockers
produce activation of ERK through -arrestin (Azzi et
al., 2003). In view of the fact that a number of -blockers
have been tested in clinical trial for therapy of conges-
tive heart failure and only a few have shown beneficial
effects (Metra et al., 2004), this ERK-stimulating effect
may be relevant. In particular, carvedilol has been iden-
tified as producing beneficial effects in congestive heart
failure, and it also has been shown to produce -arres-
tin-mediated activation of ERK (Wisler et al., 2007).
Another added property of biased ligands, in this case
antagonists, is the ability to actively internalize recep-
tors. In this way, a long-lasting blockade of signaling to
a given system can be produced by the removal of the
receptor from the cell surface. As discussed previously
(section V.A.4), this has obvious advantages for AIDS
therapy and prevention by removing the CCR5 receptor,
the site of HIV-1 entry. In addition, many tumors over-
express 7TMRs, leading to postulates that activation of
these new receptor populations support tumor progres-
sion, invasion, and metastasis (Li et al., 2005). In addi-
tion, these enormously elevated receptor populations
would be predicted to be constitutively active as well,
thereby elevating cellular second messenger levels that
would, in turn, promote tumor growth (Kenakin, 2001).
The ability of antagonists for these 7TMRs to internalize
(and thus remove from the cell surface) these receptors
without activating them would be postulated to be a
useful strategy in cancer (Bosier and Hermans, 2007).
Likewise, the ability to internalize 5-HT2A receptors has
been proposed to contribute to the unique therapeutic
profile of the antipsychotic drug clozapine (Willins et al.,
1998, 1999). In addition, reduction of 5-HT agonism in
the treatment of major depression, which may be aug-
mented by 5-HT antagonists that cause receptor inter-
nalization (Gray and Roth, 2001), has been associated
with alleviation of severely pessimistic and dysfunc-
tional attitudes in depressed patients (Meyer et al.,
2003).
VI. Conclusions
It is useful to consider 7TMRs as disordered allosteric
proteins that exhibit modulator/conduit/guest behavior
with a number of guests in the extracellular space and
cytosol. The intrinsic disorder in various regions of
7TMRs allows them to adopt numerous conformations, a
behavior pattern that can be described as the protein
rolling on an energy landscape. The binding of an allo-
steric ligand changes the thermodynamics of the protein
such that it basically moves onto a new energy land-
scape. This new landscape dictates new behaviors that
may manifest themselves as increased or decreased re-
activity to other ligands, membrane-bound proteins, or
cytosolic signaling proteins. The ability to separately
observe these behaviors shows that ligands break the
bounds of such classifications as agonist and antagonist
and can show a wide variety of mixed effects. The chal-
lenge will be to identify these phenotypes and under-
stand how they can be uniquely applied to therapeutics.
The first steps in the process of integrating appreciation
of general 7TMR allosteric behavior into new drug dis-
covery is to detect the effects through targeted pharma-
cologic assays, quantifying biased responses and control-
ling their expression in chemical scaffolds to enhance
biased effects. It is hoped that with a better understand-
ing of the complex capabilities of 7TMRs and the access
to assays that enable us to see how molecules manipu-
late 7TMR ensemble behavior, more selective and effi-
cacious drugs will emerge for testing in the clinic.
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